| 2026-07-26 | US | MNKD | MannKind | PDUFA – approvato | Furoscix ReadyFlow autorizzato dalla FDA il 23 luglio 2026 per l’edema in adulti con scompenso cardiaco o malattia renale cronica |
| 2026-08 | EU | ARGX
XBRU | argenx | Phase 2 | A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) |
| 2026-08 | EU | ZEAL
XCSE | Zealand Pharma | Phase 1 | A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants |
| 2026-08 | Ex-US | ASCLF | Ascletis Pharma Inc. | Phase 2 | A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus |
| 2026-08 | Ex-US | CASBF | CanSino Biologics Inc. | Phase 1 | A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years |
| 2026-08 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) |
| 2026-08 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Evolutionary Therapy for Rhabdomyosarcoma |
| 2026-08 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma |
| 2026-08 | Ex-US | JBPHF | Jacobio Pharmaceuticals Group Co., Ltd. | Phase 1/Phase 2 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors |
| 2026-08 | Ex-US | PYCXF | PYC THERAPEUTICS LTD. | Phase 1 | SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew) |
| 2026-08 | Ex-US | ZLDPF | Zealand Pharma A/S | Phase 1 | A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants |
| 2026-08 | US | ACIU | AC Immune SA | Phase 1 | A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants |
| 2026-08 | US | ACRS | Aclaris Therapeutics, Inc. | Phase 2 | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis |
| 2026-08 | US | AKBA | Akebia Therapeutics, Inc. | Phase 3 | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis |
| 2026-08 | US | ANRO | Alto Neuroscience, Inc. | Phase 2 | ALTO-100 in Bipolar Disorder With Depression (BD-D) |
| 2026-08 | US | RCUS | Arcus Biosciences, Inc. | Phase 3 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body |
| 2026-08 | US | AVIR | Atea Pharmaceuticals, Inc. | Phase 1 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone |
| 2026-08 | US | RNA | Avidity Biosciences, Inc. | Phase 3 | Global Study of Del-desiran for the Treatment of DM1 |
| 2026-08 | US | CADL | Candel Therapeutics, Inc. | Phase 2 | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec |
| 2026-08 | US | CPHI | China Pharma Holdings, Inc. | Phase 2 | A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus |
| 2026-08 | US | CORT | Corcept Therapeutics Incorporated | Phase 1 | Evaluation of Miricorilant on Liver Fat in Patients With MASLD |
| 2026-08 | US | CORT | Corcept Therapeutics Incorporated | Phase 2 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers |
| 2026-08 | US | CRIS | Curis, Inc. | Phase 1/Phase 2 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) |
| 2026-08 | US | HELP | Cybin Inc. | Phase 3 | “A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder” |
| 2026-08 | US | ENSC | Ensysce Biosciences, Inc. | Phase 3 | PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) |
| 2026-08 | US | EYPT | EyePoint, Inc. | Phase 3 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 |
| 2026-08 | US | IGC | IGC Pharma, Inc. | Phase 2 | Clinical Trial on Agitation in Alzheimer’s Dementia |
| 2026-08 | US | IVVD | Invivyd, Inc. | Phase 3 | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine |
| 2026-08 | US | IVVD | Invivyd, Inc. | Phase 3 | Study of VYD2311 for the Prevention of COVID-19 |
| 2026-08 | US | KPTI | Karyopharm Therapeutics Inc. | Phase 3 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma |
| 2026-08 | US | KOD | Kodiak Sciences Inc. | Phase 3 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) – DAYBREAK |
| 2026-08 | US | KURA | Kura Oncology, Inc. | Phase 1 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| 2026-08 | US | KYTX | Kyverna Therapeutics, Inc. | Phase 1/Phase 2 | KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
| 2026-08 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease |
| 2026-08 | US | MIRM | Mirum Pharmaceuticals, Inc. | Phase 3 | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) |
| 2026-08 | US | NCNA | NuCana plc | Phase 1/Phase 2 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma |
| 2026-08 | US | PHVS | Pharvaris N.V. | Phase 3 | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE |
| 2026-08 | US | RADX | Radiopharm Theranostics Limited | Phase 1 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors |
| 2026-08 | US | RIGL | Rigel Pharmaceuticals, Inc. | Phase 1/Phase 2 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) |
| 2026-08 | US | SLGL | Sol-Gel Technologies Ltd. | Phase 3 | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome |
| 2026-08 | US | GPCR | Structure Therapeutics Inc. | Phase 2 | Aleniglipron Phase 2 Body Composition Study |
| 2026-08 | US | XENE | Xenon Pharmaceuticals Inc. | Phase 3 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder |
| 2026-08-02 | US | REPL | Replimune, Inc. | PDUFA – approvazione accelerata | TUDRIQEV (vusolimogene oderparepvec-wtpg, ex RP1) con nivolumab, approvazione accelerata FDA del 6 agosto 2026 nel melanoma cutaneo avanzato non resecabile progredito dopo anti PD-1 |
| 2026-08-06 | US | MBIO | Mustang Bio, Inc. | Phase 1 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm |
| 2026-08-11 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma |
| 2026-08-12 | US | ACRV | Acrivon Therapeutics, Inc. | Phase 1 | Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors |
| 2026-08-13 | EU | ZEAL
XCSE | Zealand Pharma | Phase 2 | Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) |
| 2026-08-13 | Ex-US | ZLDPF | Zealand Pharma A/S | Phase 2 | Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) |
| 2026-08-13 | US | LNTH | Lantheus Holdings, Inc. | PDUFA | |
| 2026-08-15 | US | PMVP | PMV Pharmaceuticals, Inc. | Phase 1/Phase 2 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) |
| 2026-08-17 | EU | BIOA-B
XSTO | BioArctic | Phase 2 | Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson’s Disease and Patients With Multiple System Atrophy |
| 2026-08-19 | US | SYRE | Spyre Therapeutics, Inc. | Phase 1 | A Study of SPY002-091 in Healthy Volunteers |
| 2026-08-20 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Axitinib + Ipilimumab in Advanced Melanoma |
| 2026-08-25 | US | CLRB | Cellectar Biosciences, Inc. | Phase 1 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas |
| 2026-08-30 | Ex-US | MSCLF | Satellos Bioscience Inc. | Phase 2 | An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 |
| 2026-08-31 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children |
| 2026-08-31 | Ex-US | SNPHY | Santen Pharmaceutical Co., Ltd. | Phase 3 | A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China |
| 2026-08-31 | US | IMMP | Immutep Limited | Phase 1 | A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers |
| 2026-08-31 | US | NRIX | Nurix Therapeutics, Inc. | Phase 1 | A Study of NX-1607 in Adults With Advanced Malignancies |
| 2026-08-31 | US | VSTM | Verastem, Inc. | Phase 1/Phase 2 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer |
| 2026-09 | EU | ABVX
XPAR | Abivax | Phase 1 | Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation |
| 2026-09 | EU | ARGX
XBRU | argenx | Phase 3 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy |
| 2026-09 | Ex-US | CLRPF | Clarity Pharmaceuticals Ltd | Phase 1/Phase 2 | 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) |
| 2026-09 | Ex-US | CLRPF | Clarity Pharmaceuticals Ltd | Phase 3 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
| 2026-09 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG |
| 2026-09 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3) |
| 2026-09 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 1 | Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects |
| 2026-09 | US | APGE | Apogee Therapeutics, Inc. | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma |
| 2026-09 | US | ATXS | Astria Therapeutics, Inc. | Phase 1 | A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants |
| 2026-09 | US | AVIR | Atea Pharmaceuticals, Inc. | Phase 3 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV |
| 2026-09 | US | BHVN | Biohaven Ltd. | Phase 2 | Taldefgrobep Alfa in Adults With Overweight and Obesity |
| 2026-09 | US | CRVO | CervoMed Inc. | Phase 2 | Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia |
| 2026-09 | US | CORT | Corcept Therapeutics Incorporated | Phase 1/Phase 2 | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies |
| 2026-09 | US | CORT | Corcept Therapeutics Incorporated | Phase 2 | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) |
| 2026-09 | US | CGEM | Cullinan Therapeutics, Inc. | Phase 1 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma |
| 2026-09 | US | DSGN | Design Therapeutics, Inc. | Phase 2 | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy |
| 2026-09 | US | IRON | Disc Medicine, Inc. | Phase 3 | Study of Bitopertin in Participants With EPP or XLP (APOLLO) |
| 2026-09 | US | EWTX | Edgewise Therapeutics, Inc. | Phase 2 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) |
| 2026-09 | US | KPTI | Karyopharm Therapeutics Inc. | Phase 2 | A Study to Evaluate Single Agent Selinexor Versus Physician’s Choice in Participants With Previously Treated Myelofibrosis |
| 2026-09 | US | LNTH | Lantheus Holdings, Inc. | Phase 1 | Test-retest Study With [18F]FBB in Cardiac Amyloidosis |
| 2026-09 | US | MAZE | Maze Therapeutics, Inc. | Phase 2 | A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease |
| 2026-09 | US | NAMS | NewAmsterdam Pharma Company N.V. | Phase 2 | Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers |
| 2026-09 | US | ORIC | ORIC Pharmaceuticals, Inc. | Phase 1/Phase 2 | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration |
| 2026-09 | US | PCSA | Processa Pharmaceuticals, Inc. | Phase 2 | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer |
| 2026-09 | US | RAPP | Rapport Therapeutics, Inc. | Phase 2 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder |
| 2026-09 | US | RGNX | REGENXBIO Inc. | Phase 2/Phase 3 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) |
| 2026-09 | US | SLN | Silence Therapeutics plc | Phase 1/Phase 2 | Study to Assess SLN124 in Patients With Polycythemia Vera |
| 2026-09 | US | STJO | St. Joseph, Inc. | Phase 2 | Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer |
| 2026-09 | US | GPCR | Structure Therapeutics Inc. | Phase 2 | Aleniglipron Phase 2 in Type 2 Diabetes Mellitus |
| 2026-09 | US | SUPN | Supernus Pharmaceuticals, Inc. | Phase 3 | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) |
| 2026-09 | US | SNDX | Syndax Pharmaceuticals, Inc. | Phase 2 | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
| 2026-09 | US | TNGX | Tango Therapeutics, Inc. | Phase 1/Phase 2 | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors |
| 2026-09 | US | TLSA | Tiziana Life Sciences Ltd | Phase 2 | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients |
| 2026-09 | US | TYRA | Tyra Biosciences, Inc. | Phase 1 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations |
| 2026-09 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 2 | An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye |
| 2026-09 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 2 | Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis |
| 2026-09 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 3 | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) |
| 2026-09 | US | VERA | Vera Therapeutics, Inc. | Phase 2 | Monthly Dosing of Atacicept in IgAN |
| 2026-09 | US | WVE | Wave Life Sciences Ltd. | Phase 1/Phase 2 | A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD |
| 2026-09-01 | US | ARDX | Ardelyx, Inc. | Phase 3 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
| 2026-09-04 | Ex-US | SHEZF | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Phase 1 | A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors |
| 2026-09-05 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 3 | A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine |
| 2026-09-15 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | A Trial of Lu AG13909 in Adult Participants With Cushing’s Disease |
| 2026-09-21 | US | CRDL | Cardiol Therapeutics Inc. | Phase 3 | CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) |
| 2026-09-25 | US | VIR | Vir Biotechnology, Inc. | Phase 1 | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 |
| 2026-09-28 | US | MLTX | MoonLake Immunotherapeutics | Phase 3 | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) |
| 2026-09-28 | US | OCGN | Ocugen, Inc. | Phase 2/Phase 3 | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease |
| 2026-09-30 | EU | ARGX
XBRU | argenx | Phase 2/Phase 3 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis |
| 2026-09-30 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1/Phase 2 | A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia |
| 2026-09-30 | Ex-US | SYMQY | SymBio Pharmaceuticals Limited | Phase 2 | A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection |
| 2026-09-30 | US | ALEC | Alector, Inc. | Phase 2 | Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer’s Disease |
| 2026-09-30 | US | ATRA | Atara Biotherapeutics, Inc. | Phase 1 | Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma |
| 2026-09-30 | US | CHRS | Coherus Oncology, Inc. | Phase 1 | Study of CHS-114 in Participants With Advanced Solid Tumors |
| 2026-09-30 | US | MAJI | Marijuana Inc. | Phase 1/Phase 2 | Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI |
| 2026-09-30 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial |
| 2026-09-30 | US | RPTX | Repare Therapeutics Inc. | Phase 1/Phase 2 | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer |
| 2026-09-30 | US | QURE | uniQure N.V. | Phase 1/Phase 2 | Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) |
| 2026-10 | EU | PHM*
XMAD | PharmaMar | Phase 1 | PM534 Administered Intravenously to Patients With Advanced Solid Tumors |
| 2026-10 | EU | PHARM
XAMS | Pharming | Phase 2 | Leniolisib for Immune Dysregulation in CVID |
| 2026-10 | EU | PHIL
XMIL | Philogen | Phase 1/Phase 2 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma |
| 2026-10 | Ex-US | ATGGF | Actinogen Medical Limited | Phase 2/Phase 3 | Effect of 10 mg Xanamem on Dementia Due to Alzheimer’s Disease |
| 2026-10 | Ex-US | CASBF | CanSino Biologics Inc. | Phase 1 | Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine |
| 2026-10 | Ex-US | CASBF | CanSino Biologics Inc. | Phase 1/Phase 2 | A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers |
| 2026-10 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 2 | Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis |
| 2026-10 | US | ABOS | Acumen Pharmaceuticals, Inc. | Phase 2 | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer’s Disease (ALTITUDE-AD) |
| 2026-10 | US | AKBA | Akebia Therapeutics, Inc. | Phase 1 | SAD and MAD Study of AKB-9090 in Healthy Adult Participants |
| 2026-10 | US | BCRX | BioCryst Pharmaceuticals, Inc. | Phase 1 | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 |
| 2026-10 | US | BHVN | Biohaven Ltd. | Phase 2/Phase 3 | Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy |
| 2026-10 | US | CLDX | Celldex Therapeutics, Inc. | Phase 3 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) |
| 2026-10 | US | CLDX | Celldex Therapeutics, Inc. | Phase 3 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria |
| 2026-10 | US | CORT | Corcept Therapeutics Incorporated | Phase 2 | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis |
| 2026-10 | US | IRON | Disc Medicine, Inc. | Phase 2 | Study of DISC-0974-201 in Participants With IBD and Anemia |
| 2026-10 | US | EYPT | EyePoint, Inc. | Phase 3 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 |
| 2026-10 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 1 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors |
| 2026-10 | US | IMCR | Immunocore Holdings plc | Phase 1/Phase 2 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors |
| 2026-10 | US | ITRM | Iterum Therapeutics plc | Phase 1 | Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents |
| 2026-10 | US | JBIO | Jade Biosciences, Inc. | Phase 1 | A Phase 1 Study of JADE101 in Healthy Participants |
| 2026-10 | US | KZIA | Kazia Therapeutics Limited | Phase 2 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases |
| 2026-10 | US | MIRM | Mirum Pharmaceuticals, Inc. | Phase 3 | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) |
| 2026-10 | US | NTHI | NeOnc Technologies Holdings, Inc. | Phase 1 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors |
| 2026-10 | US | OGN | Organon & Co. | Phase 3 | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects |
| 2026-10 | US | PHAR | Pharming Group N.V. | Phase 2 | Leniolisib for Immune Dysregulation in CVID |
| 2026-10 | US | PHAT | Phathom Pharmaceuticals, Inc. | Phase 2 | A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks |
| 2026-10 | US | SRNE | Sorrento Therapeutics, Inc. | Phase 1 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors |
| 2026-10 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 2 | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension |
| 2026-10 | US | XENE | Xenon Pharmaceuticals Inc. | Phase 3 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) |
| 2026-10-01 | EU | ARGX
XBRU | argenx | Phase 3 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia |
| 2026-10-01 | US | COCP | Cocrystal Pharma, Inc. | Phase 1/Phase 2 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus |
| 2026-10-01 | US | MJNA | Medical Marijuana, Inc. | Phase 2/Phase 3 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer |
| 2026-10-02 | US | FTRE | Fortrea Holdings Inc. | Phase 1 | AZD5305 hADME in Patients With Advanced Solid Malignancies |
| 2026-10-02 | US | PSTV | Plus Therapeutics, Inc. | Phase 1 | Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases |
| 2026-10-05 | EU | SOBI
XSTO | Swedish Orphan Biovitrum | Phase 3 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
| 2026-10-15 | US | SLDB | Solid Biosciences Inc. | Phase 1/Phase 2 | Microdystrophin Gene Transfer Study in Adolescents and Children With DMD |
| 2026-10-16 | US | IOBT | IO Biotech, Inc. | Phase 2 | Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). |
| 2026-10-24 | US | PHAR | Pharming Group N.V. | PDUFA – CRL | |
| 2026-10-30 | US | CORT | Corcept Therapeutics Incorporated | Phase 1 | Evaluating the Pharmacokinetics and Safety of Miricorilant |
| 2026-10-30 | US | INO | INOVIO Pharmaceuticals, Inc. | PDUFA | |
| 2026-10-30 | US | MBX | MBX Biosciences, Inc. | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity |
| 2026-10-31 | US | ADAG | Adagene Inc. | Phase 1/Phase 2 | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors |
| 2026-10-31 | US | ANNX | Annexon, Inc. | Phase 3 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) |
| 2026-10-31 | US | REPL | Replimune, Inc. | Phase 1 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors |
| 2026-10-31 | US | SRPT | Sarepta Therapeutics, Inc. | Phase 3 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) |
| 2026-10-31 | US | SYRE | Spyre Therapeutics, Inc. | Phase 2 | A Study of SPY072 in Rheumatic Disease |
| 2026-10-31 | US | TGTX | TG Therapeutics, Inc. | Phase 3 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) |
| 2026-11 | EU | ARGX
XBRU | argenx | Phase 2 | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis |
| 2026-11 | EU | CAMX
XSTO | Camurus | Phase 3 | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET |
| 2026-11 | EU | DBV
XPAR | DBV Technologies | Phase 3 | Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) |
| 2026-11 | EU | PHARM
XAMS | Pharming | Phase 2 | Leniolisib for Immune Dysregulation in PIDs |
| 2026-11 | Ex-US | APTOF | Aptose Biosciences Inc. | Phase 1/Phase 2 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| 2026-11 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma |
| 2026-11 | Ex-US | MCUJF | Medicure Inc. | Phase 3 | Oral Pyridoxal 5′-Phosphate for the Treatment of Patients With PNPO Deficiency |
| 2026-11 | US | ANL | Adlai Nortye Ltd. | Phase 1 | First in Human, Dose Escalation Study of AN4005 |
| 2026-11 | US | APGE | Apogee Therapeutics, Inc. | Phase 2 | A Study Evaluating APG777 in Atopic Dermatitis |
| 2026-11 | US | RCUS | Arcus Biosciences, Inc. | Phase 1 | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies |
| 2026-11 | US | ATOS | Atossa Therapeutics, Inc. | Phase 2 | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer |
| 2026-11 | US | BHVN | Biohaven Ltd. | Phase 1 | A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia |
| 2026-11 | US | DRUG | Bright Minds Biosciences Inc. | Phase 2 | A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. |
| 2026-11 | US | CRDF | Cardiff Oncology, Inc. | Phase 2 | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation |
| 2026-11 | US | CGON | CG Oncology, Inc. | Phase 3 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT |
| 2026-11 | US | CGEM | Cullinan Therapeutics, Inc. | Phase 1 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) |
| 2026-11 | US | DBVT | DBV Technologies S.A. | Phase 3 | Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) |
| 2026-11 | US | IMUX | Immunic, Inc. | Phase 3 | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis |
| 2026-11 | US | IMUX | Immunic, Inc. | Phase 3 | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis |
| 2026-11 | US | KPRX | Kiora Pharmaceuticals, Inc. | Phase 2 | Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema |
| 2026-11 | US | MGNX | MacroGenics, Inc. | Phase 1 | A Study of MGC028 in Participants With Advanced Solid Tumors |
| 2026-11 | US | MGNX | MacroGenics, Inc. | Phase 1 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies |
| 2026-11 | US | NAMS | NewAmsterdam Pharma Company N.V. | Phase 2 | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels |
| 2026-11 | US | NAMS | NewAmsterdam Pharma Company N.V. | Phase 3 | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease |
| 2026-11 | US | PHAR | Pharming Group N.V. | Phase 2 | Leniolisib for Immune Dysregulation in PIDs |
| 2026-11 | US | TYRA | Tyra Biosciences, Inc. | Phase 1/Phase 2 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations |
| 2026-11 | US | VIR | Vir Biotechnology, Inc. | Phase 2 | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection |
| 2026-11 | US | ZURA | Zura Bio Limited | Phase 2 | Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense |
| 2026-11-01 | US | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Phase 1/Phase 2 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. |
| 2026-11-01 | US | MJNA | Medical Marijuana, Inc. | Phase 1 | The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study |
| 2026-11-01 | US | SRRK | Scholar Rock Holding Corporation | Phase 3 | Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab |
| 2026-11-05 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1/Phase 2 | Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases |
| 2026-11-05 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis |
| 2026-11-18 | US | SYRE | Spyre Therapeutics, Inc. | Phase 1 | A Study of SPY003-207 in Healthy Volunteers |
| 2026-11-20 | US | SKYE | Skye Bioscience, Inc. | Phase 2 | Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo |
| 2026-11-22 | Ex-US | RVXCF | Resverlogix Corp. | Phase 1/Phase 2 | A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis |
| 2026-11-24 | Ex-US | CASBF | CanSino Biologics Inc. | Phase 1/Phase 2 | Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) |
| 2026-11-24 | US | TECX | Tectonic Therapeutic, Inc. | Phase 2 | A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) |
| 2026-11-25 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 3 | ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis |
| 2026-11-30 | EU | BAVA
XCSE | Bavarian Nordic | Phase 2 | Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells |
| 2026-11-30 | EU | PHARM
XAMS | Pharming | Phase 3 | Pediatric Patients Aged 4 to 11 Years With APDS |
| 2026-11-30 | Ex-US | BVNRY | Bavarian Nordic A/S | Phase 2 | Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells |
| 2026-11-30 | US | AURA | Aura Biosciences, Inc. | Phase 2 | Suprachoroidal Administration in Subjects With Metastases to the Choroid |
| 2026-11-30 | US | BIOA | BioAge Labs, Inc. | Phase 2 | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors |
| 2026-11-30 | US | RNAC | Cartesian Therapeutics, Inc. | Phase 3 | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis |
| 2026-11-30 | US | IMCR | Immunocore Holdings plc | Phase 1/Phase 2 | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers |
| 2026-11-30 | US | PHAR | Pharming Group N.V. | Phase 3 | Pediatric Patients Aged 4 to 11 Years With APDS |
| 2026-11-30 | US | REPL | Replimune, Inc. | Phase 1 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours |
| 2026-11-30 | US | QURE | uniQure N.V. | Phase 1/Phase 2 | AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy |
| 2026-12 | EU | ABVX
XPAR | Abivax | Phase 2 | Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn’s Disease |
| 2026-12 | EU | ARGX
XBRU | argenx | Phase 1 | A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants |
| 2026-12 | EU | PHIL
XMIL | Philogen | Phase 1 | Safety and Early Signs of Efficacy of IL12-L19L19. |
| 2026-12 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 2 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL |
| 2026-12 | Ex-US | BRIBF | Brii Biosciences Limited | Phase 2 | Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) |
| 2026-12 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL |
| 2026-12 | Ex-US | TLTFF | Theralase Technologies Inc. | Phase 2 | Intravesical Photodynamic Therapy (“PDT”) in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (“NMIBC”) Patients |
| 2026-12 | US | ALDX | ALDEYRA THERAPEUTICS, INC. | Phase 3 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma |
| 2026-12 | US | ANRO | Alto Neuroscience, Inc. | Phase 2 | Study of ALTO-300 in MDD |
| 2026-12 | US | APGE | Apogee Therapeutics, Inc. | Phase 1 | An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis |
| 2026-12 | US | RCUS | Arcus Biosciences, Inc. | Phase 1 | A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants |
| 2026-12 | US | ATXS | Astria Therapeutics, Inc. | Phase 3 | A Study of Navenibart in Participants With Hereditary Angioedema |
| 2026-12 | US | AVIR | Atea Pharmaceuticals, Inc. | Phase 1 | Study of AT-587 in Healthy Subjects |
| 2026-12 | US | AVIR | Atea Pharmaceuticals, Inc. | Phase 3 | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV |
| 2026-12 | US | BEAM | Beam Therapeutics Inc. | Phase 1/Phase 2 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) |
| 2026-12 | US | BCDA | BioCardia, Inc. | Phase 1/Phase 2 | Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells |
| 2026-12 | US | BHVN | Biohaven Ltd. | Phase 2 | Long-term Safety and Tolerability of BHV-7000 |
| 2026-12 | US | BHVN | Biohaven Ltd. | Phase 2/Phase 3 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy |
| 2026-12 | US | BRTX | BioRestorative Therapies, Inc. | Phase 2 | A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD) |
| 2026-12 | US | CNTA | Centessa Pharmaceuticals plc | Phase 2 | A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia |
| 2026-12 | US | CMPX | Compass Therapeutics, Inc. | Phase 1 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies |
| 2026-12 | US | CNTX | Context Therapeutics Inc. | Phase 1 | CT-95 in Advanced Cancers Associated With Mesothelin Expression |
| 2026-12 | US | CORT | Corcept Therapeutics Incorporated | Phase 2 | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome |
| 2026-12 | US | CGEM | Cullinan Therapeutics, Inc. | Phase 1 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus |
| 2026-12 | US | DCTH | Delcath Systems, Inc. | Phase 2 | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease |
| 2026-12 | US | DNLI | Denali Therapeutics Inc. | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) |
| 2026-12 | US | DSGN | Design Therapeutics, Inc. | Phase 1/Phase 2 | A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich’s Ataxia |
| 2026-12 | US | DMAC | DiaMedica Therapeutics Inc. | Phase 2/Phase 3 | Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) |
| 2026-12 | US | EIKN | Eikon Therapeutics, Inc. | Phase 2 | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC |
| 2026-12 | US | EPRX | Eupraxia Pharmaceuticals Inc. | Phase 1/Phase 2 | A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). |
| 2026-12 | US | GNLX | Genelux Corporation | Phase 3 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician’s Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
| 2026-12 | US | GOSS | Gossamer Bio, Inc. | Phase 3 | Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) |
| 2026-12 | US | IMMX | Immix Biopharma, Inc. | Phase 1/Phase 2 | Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis |
| 2026-12 | US | ZJYL | Jin Medical International Ltd. | Phase 2 | Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis |
| 2026-12 | US | KPTI | Karyopharm Therapeutics Inc. | Phase 2 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
| 2026-12 | US | KPTI | Karyopharm Therapeutics Inc. | Phase 2/Phase 3 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| 2026-12 | US | KZIA | Kazia Therapeutics Limited | Phase 1 | GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases |
| 2026-12 | US | LXEO | Lexeo Therapeutics, Inc. | Phase 1/Phase 2 | Gene Therapy for ACM Due to a PKP2 Pathogenic Variant |
| 2026-12 | US | MDWD | MediWound Ltd. | Phase 3 | A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) |
| 2026-12 | US | MNPR | Monopar Therapeutics Inc. | Phase 1 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors |
| 2026-12 | US | NXTC | NextCure, Inc. | Phase 1 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors |
| 2026-12 | US | NVCT | Nuvectis Pharma, Inc. | Phase 1 | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer |
| 2026-12 | US | OMER | Omeros Corporation | Phase 2 | Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria |
| 2026-12 | US | ORIC | ORIC Pharmaceuticals, Inc. | Phase 1 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC |
| 2026-12 | US | PRAX | Praxis Precision Medicines, Inc. | Phase 3 | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine |
| 2026-12 | US | PRAX | Praxis Precision Medicines, Inc. | Phase 3 | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety |
| 2026-12 | US | PMN | ProMIS Neurosciences, Inc. | Phase 1 | PMN310 in Patients With Early Alzheimer’s Disease (PRECISE-AD) |
| 2026-12 | US | TARA | Protara Therapeutics, Inc. | Phase 2 | Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
| 2026-12 | US | STJO | St. Joseph, Inc. | Phase 3 | Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas |
| 2026-12 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 3 | Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder |
| 2026-12 | US | VIR | Vir Biotechnology, Inc. | Phase 3 | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide |
| 2026-12 | US | ZYME | Zymeworks Inc. | Phase 1 | A Study of ZW191 in Participants With Solid Tumors |
| 2026-12-01 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 1/Phase 2 | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma |
| 2026-12-01 | US | ABUS | Arbutus Biopharma Corporation | Phase 2 | Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B |
| 2026-12-01 | US | RNAC | Cartesian Therapeutics, Inc. | Phase 2 | Descartes-08 for Patients With Systemic Lupus Erythematosus |
| 2026-12-01 | US | CMPX | Compass Therapeutics, Inc. | Phase 2/Phase 3 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) |
| 2026-12-01 | US | KZIA | Kazia Therapeutics Limited | Phase 2 | Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL |
| 2026-12-01 | US | MJNA | Medical Marijuana, Inc. | Phase 1/Phase 2 | Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 |
| 2026-12-01 | US | RANI | Rani Therapeutics Holdings, Inc. | Phase 1 | An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. |
| 2026-12-01 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 3 | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use |
| 2026-12-01 | US | ZNTL | Zentalis Pharmaceuticals, Inc. | Phase 2 | A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| 2026-12-04 | EU | VLA
XPAR | Valneva | Phase 3
partner: Pfizer | A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine |
| 2026-12-15 | Ex-US | GEDSF | Gedeon Richter PLC | Phase 3 | Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia |
| 2026-12-17 | US | SRRK | Scholar Rock Holding Corporation | Phase 1 | A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults |
| 2026-12-22 | US | ENSC | Ensysce Biosciences, Inc. | Phase 1 | Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) |
| 2026-12-28 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 1/Phase 2 | A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) |
| 2026-12-30 | EU | BSLN
XSWX | Basilea Pharmaceutica | Phase 1 | Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination |
| 2026-12-30 | EU | PHM*
XMAD | PharmaMar | Phase 1 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. |
| 2026-12-30 | EU | SOBI
XSTO | Swedish Orphan Biovitrum | Phase 2 | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) |
| 2026-12-30 | Ex-US | ABSCF | AB Science S.A. | Phase 1/Phase 2 | A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer |
| 2026-12-30 | Ex-US | PSYGF | Psyence Group Inc. | Phase 2 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder |
| 2026-12-30 | US | HOTH | Hoth Therapeutics, Inc. | Phase 2 | Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors |
| 2026-12-30 | US | NTHI | NeOnc Technologies Holdings, Inc. | Phase 2 | NEO100 and High-Grade Meningioma |
| 2026-12-30 | US | SUPN | Supernus Pharmaceuticals, Inc. | Phase 1/Phase 2 | BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures |
| 2026-12-30 | US | TCRX | TScan Therapeutics, Inc. | Phase 1 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors |
| 2026-12-31 | EU | ARGX
XBRU | argenx | Phase 1 | A Study to Assess the Safety of ARGX-124 in Healthy Volunteers |
| 2026-12-31 | EU | NWRN
XSWX | Newron Pharmaceuticals | Phase 3 | Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia |
| 2026-12-31 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 3 | Global Trial in APG2575 for Patients With CLL/SLL |
| 2026-12-31 | Ex-US | CRTHF | CARsgen Therapeutics Holdings Limited | Phase 1 | A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer |
| 2026-12-31 | Ex-US | CRTHF | CARsgen Therapeutics Holdings Limited | Phase 1 | CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection |
| 2026-12-31 | Ex-US | CLRPF | Clarity Pharmaceuticals Ltd | Phase 3 | 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer |
| 2026-12-31 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1/Phase 2 | Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye |
| 2026-12-31 | Ex-US | JBPHF | Jacobio Pharmaceuticals Group Co., Ltd. | Phase 1/Phase 2 | A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration |
| 2026-12-31 | Ex-US | JCRRF | JCR Pharmaceuticals Co., Ltd. | Phase 2 | An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II |
| 2026-12-31 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 1 | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia |
| 2026-12-31 | US | FOLD | Amicus Therapeutics, Inc. | Phase 3 | A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease |
| 2026-12-31 | US | ANNX | Annexon, Inc. | Phase 3 | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) |
| 2026-12-31 | US | BCAX | Bicara Therapeutics Inc. | Phase 1 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors |
| 2026-12-31 | US | ESLA | Estrella Immunopharma, Inc. | Phase 1/Phase 2 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) |
| 2026-12-31 | US | FBRX | Forte Biosciences, Inc. | Phase 1 | A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo |
| 2026-12-31 | US | GOVX | GeoVax Labs, Inc. | Phase 2 | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
| 2026-12-31 | US | INO | INOVIO Pharmaceuticals, Inc. | Phase 1/Phase 2 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) |
| 2026-12-31 | US | MJNA | Medical Marijuana, Inc. | Phase 1/Phase 2 | Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer |
| 2026-12-31 | US | MJNA | Medical Marijuana, Inc. | Phase 2/Phase 3 | Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma |
| 2026-12-31 | US | PHIO | Phio Pharmaceuticals Corp. | Phase 1 | Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors |
| 2026-12-31 | US | STJO | St. Joseph, Inc. | Phase 3 | Multiprofen-CC to Reduce Pain in Hand Arthritis |
| 2026-12-31 | US | SUPN | Supernus Pharmaceuticals, Inc. | Phase 2 | Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder |
| 2026-12-31 | US | VIR | Vir Biotechnology, Inc. | Phase 3 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection |
| 2027-01 | Ex-US | CSPHF | CStone Pharmaceuticals | Phase 1/Phase 2 | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors |
| 2027-01 | Ex-US | HOPHF | Hemogenyx Pharmaceuticals Plc | Phase 1 | Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML |
| 2027-01 | Ex-US | JBPHF | Jacobio Pharmaceuticals Group Co., Ltd. | Phase 1/Phase 2 | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation |
| 2027-01 | US | RCUS | Arcus Biosciences, Inc. | Phase 2 | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies |
| 2027-01 | US | CALC | CalciMedica, Inc. | Phase 1/Phase 2 | Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase |
| 2027-01 | US | COYA | Coya Therapeutics, Inc. | Phase 2/Phase 3 | Study of COYA 302 for the Treatment of ALS |
| 2027-01 | US | CGEM | Cullinan Therapeutics, Inc. | Phase 1 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
| 2027-01 | US | EWTX | Edgewise Therapeutics, Inc. | Phase 2 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) |
| 2027-01 | US | ELDN | Eledon Pharmaceuticals, Inc. | Phase 1/Phase 2 | Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant |
| 2027-01 | US | ELVN | Enliven Therapeutics, Inc. | Phase 1 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer |
| 2027-01 | US | KURA | Kura Oncology, Inc. | Phase 1 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors |
| 2027-01 | US | LRMR | Larimar Therapeutics, Inc. | Phase 2 | An Open-Label Study of CTI-1601 in Subjects With Friedreich’s Ataxia |
| 2027-01 | US | NRIX | Nurix Therapeutics, Inc. | Phase 1 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies |
| 2027-01 | US | NUVL | Nuvalent, Inc. | Phase 1 | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) |
| 2027-01 | US | ORKA | Oruka Therapeutics, Inc. | Phase 1 | ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose |
| 2027-01 | US | PRAX | Praxis Precision Medicines, Inc. | Phase 3 | Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures |
| 2027-01 | US | SGMT | Sagimet Biosciences Inc. | Phase 1 | Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne |
| 2027-01 | US | STJO | St. Joseph, Inc. | Phase 1/Phase 2 | Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase |
| 2027-01 | US | TLX | Telix Pharmaceuticals Limited | Phase 3 | PSMA PET Combined With MRI for the Detection of PCa |
| 2027-01 | US | RARE | Ultragenyx Pharmaceutical Inc. | Phase 3 | Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta |
| 2027-01 | US | XENE | Xenon Pharmaceuticals Inc. | Phase 3 | An Open-Label Study of Azetukalner in Major Depressive Disorder |
| 2027-01 | US | ZVRA | Zevra Therapeutics, Inc. | Phase 2 | Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) |
| 2027-01-01 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 1 | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
| 2027-01-01 | US | PYPD | PolyPid Ltd. | PDUFA | |
| 2027-01-04 | Ex-US | PHCUF | Photocure ASA | Phase 3 | Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection |
| 2027-01-07 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 1 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion |
| 2027-01-08 | US | FTRE | Fortrea Holdings Inc. | Phase 3 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration |
| 2027-01-08 | US | OCUL | Ocular Therapeutix, Inc. | Phase 3 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration |
| 2027-01-10 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI |
| 2027-01-13 | US | FTRE | Fortrea Holdings Inc. | Phase 3 | A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab |
| 2027-01-15 | US | AZTR | Azitra, Inc. | Phase 1/Phase 2 | A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity |
| 2027-01-15 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 2/Phase 3 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma |
| 2027-01-15 | US | MLTX | MoonLake Immunotherapeutics | Phase 3 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response |
| 2027-01-15 | US | XBIT | XBiotech Inc. | Phase 2 | Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment |
| 2027-01-16 | US | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Phase 1/Phase 2 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors |
| 2027-01-29 | US | DVAX | Dynavax Technologies Corporation | Phase 2 | Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age |
| 2027-01-29 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 1/Phase 2 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions |
| 2027-01-30 | Ex-US | ABSCF | AB Science S.A. | Phase 2 | Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder |
| 2027-01-31 | Ex-US | SCNLF | Scancell Holdings plc | Phase 2 | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) |
| 2027-01-31 | US | APLM | Apollomics, Inc. | Phase 1/Phase 2 | Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) |
| 2027-01-31 | US | CELZ | Creative Medical Technology Holdings, Inc. | Phase 1/Phase 2 | Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes |
| 2027-01-31 | US | CUE | Cue Biopharma, Inc. | Phase 1 | CUE-102 in Recurrent Glioblastoma |
| 2027-01-31 | US | QNRX | Quoin Pharmaceuticals, Ltd. | Phase 2/Phase 3 | Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome |
| 2027-02 | EU | ALM*
XMAD | Almirall | Phase 2 | A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa |
| 2027-02 | EU | ARGX
XBRU | argenx | Phase 2 | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis |
| 2027-02 | EU | BAVA
XCSE | Bavarian Nordic | Phase 2 | A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine |
| 2027-02 | EU | GMAB
XCSE | Genmab | Phase 3 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer |
| 2027-02 | Ex-US | ALMRY | Almirall SA | Phase 2 | A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa |
| 2027-02 | Ex-US | LBTSF | Almirall, S.A. | Phase 2 | A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa |
| 2027-02 | Ex-US | BVNRY | Bavarian Nordic A/S | Phase 2 | A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine |
| 2027-02 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1/Phase 2 | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases |
| 2027-02 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab |
| 2027-02 | US | SXTP | 60 Degrees Pharmaceuticals, Inc. | Phase 2 | B-FREE Chronic Babesiosis Study |
| 2027-02 | US | ABCL | AbCellera Biologics Inc. | Phase 1/Phase 2 | Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause |
| 2027-02 | US | AMLX | Amylyx Pharmaceuticals, Inc. | Phase 1 | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis |
| 2027-02 | US | DAWN | Day One Biopharmaceuticals, Inc. | Phase 1/Phase 2 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors |
| 2027-02 | US | DNLI | Denali Therapeutics Inc. | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer’s Disease |
| 2027-02 | US | IRON | Disc Medicine, Inc. | Phase 2 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) |
| 2027-02 | US | ENLV | Enlivex Therapeutics Ltd. | Phase 2 | Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis |
| 2027-02 | US | FBRX | Forte Biosciences, Inc. | Phase 1 | A Study Testing the Safety and Effects of FB102 in Healthy Volunteers |
| 2027-02 | US | GNLX | Genelux Corporation | Phase 2 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer |
| 2027-02 | US | GERN | Geron Corporation | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis |
| 2027-02 | US | KOD | Kodiak Sciences Inc. | Phase 3 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) – PINNACLE |
| 2027-02 | US | SEPN | Septerna, Inc. | Phase 1 | A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants |
| 2027-02 | US | SNDX | Syndax Pharmaceuticals, Inc. | Phase 1 | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias |
| 2027-02 | US | XNCR | Xencor, Inc. | Phase 1 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma |
| 2027-02-01 | Ex-US | INNMF | Amplia Therapeutics Limited | Phase 1/Phase 2 | ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer |
| 2027-02-01 | US | TVRD | Tvardi Therapeutics, Inc. | Phase 1/Phase 2 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma |
| 2027-02-02 | US | NUVB | Nuvation Bio Inc. | Phase 1 | Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib |
| 2027-02-04 | US | MLTX | MoonLake Immunotherapeutics | Phase 3 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug |
| 2027-02-06 | US | ZLAB | Zai Lab Limited | Phase 1 | A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers |
| 2027-02-12 | US | OCGN | Ocugen, Inc. | Phase 3 | A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa |
| 2027-02-15 | Ex-US | CASBF | CanSino Biologics Inc. | Phase 3 | A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) |
| 2027-02-15 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML |
| 2027-02-26 | US | ARDX | Ardelyx, Inc. | Phase 3 | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults |
| 2027-02-27 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Clinical Trial of Green Tea Catechins in Men on Active Surveillance |
| 2027-02-28 | EU | HNSA
XSTO | Hansa Biopharma | Phase 2 | Imlifidase Prior to Kidney Transplant in Highly Sensitised Children |
| 2027-02-28 | US | FBRX | Forte Biosciences, Inc. | Phase 2 | Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease |
| 2027-02-28 | US | INSP | Inspire Medical Systems, Inc. | Phase 3 | Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea |
| 2027-02-28 | US | NTHI | NeOnc Technologies Holdings, Inc. | Phase 1/Phase 2 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis |
| 2027-03 | EU | ARGX
XBRU | argenx | Phase 1 | A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants |
| 2027-03 | EU | ARGX
XBRU | argenx | Phase 2/Phase 3 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis |
| 2027-03 | EU | FARON*
XHEL | Faron Pharmaceuticals | Phase 1/Phase 2 | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies |
| 2027-03 | EU | GMAB
XCSE | Genmab | Phase 2 | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma |
| 2027-03 | EU | SOBI
XSTO | Swedish Orphan Biovitrum | Phase 3 | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
| 2027-03 | Ex-US | ACHFF | Arch Biopartners Inc. | Phase 2 | LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery |
| 2027-03 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma |
| 2027-03 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 2 | Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study |
| 2027-03 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 2 | Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis |
| 2027-03 | US | FDMT | 4D Molecular Therapeutics, Inc. | Phase 1/Phase 2 | 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration |
| 2027-03 | US | ALGS | Aligos Therapeutics, Inc. | Phase 2 | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) |
| 2027-03 | US | ALLR | Allarity Therapeutics, Inc. | Phase 2 | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer |
| 2027-03 | US | ACLX | Arcellx, Inc. | Phase 1 | A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases |
| 2027-03 | US | AURA | Aura Biosciences, Inc. | Phase 1 | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer |
| 2027-03 | US | BMEA | Biomea Fusion, Inc. | Phase 2 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets |
| 2027-03 | US | CLDX | Celldex Therapeutics, Inc. | Phase 1 | A Study of CDX-622 in Participants With Mild to Moderate Asthma |
| 2027-03 | US | CGEN | Compugen Ltd. | Phase 1/Phase 2 | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer |
| 2027-03 | US | DNLI | Denali Therapeutics Inc. | Phase 2 | Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD) |
| 2027-03 | US | EWTX | Edgewise Therapeutics, Inc. | Phase 2 | Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy |
| 2027-03 | US | MNKD | MannKind | Phase 2 | INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes |
| 2027-03 | US | NUVB | Nuvation Bio Inc. | Phase 1/Phase 2 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors |
| 2027-03 | US | NVCT | Nuvectis Pharma, Inc. | Phase 1 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers |
| 2027-03 | US | OCGN | Ocugen, Inc. | Phase 1/Phase 2 | Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis |
| 2027-03 | US | OCUL | Ocular Therapeutix, Inc. | Phase 3 | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy |
| 2027-03 | US | PEPG | PepGen Inc. | Phase 2 | A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 |
| 2027-03 | US | PSTV | Plus Therapeutics, Inc. | Phase 1 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma |
| 2027-03 | US | PMVP | PMV Pharmaceuticals, Inc. | Phase 1 | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. |
| 2027-03 | US | STOK | Stoke Therapeutics, Inc. | Phase 3 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome |
| 2027-03 | US | URGN | UroGen Pharma Ltd. | Phase 3 | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer |
| 2027-03-01 | US | SXTP | 60 Degrees Pharmaceuticals, Inc. | Phase 2 | Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis |
| 2027-03-01 | US | THAR | Tharimmune, Inc. | Phase 2 | TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis |
| 2027-03-08 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 1 | Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia |
| 2027-03-08 | Ex-US | ORYZF | Oryzon Genomics S.A. | Phase 1 | Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia |
| 2027-03-10 | US | FBRX | Forte Biosciences, Inc. | Phase 1 | A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. |
| 2027-03-12 | US | TVTX | Travere Therapeutics, Inc. | Phase 2 | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases |
| 2027-03-14 | US | ZLAB | Zai Lab Limited | Phase 3 | A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease |
| 2027-03-18 | US | HELP | Cybin Inc. | Phase 3 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder |
| 2027-03-31 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 3 | A Study of Olverembatinib in SDH-deficient GIST. |
| 2027-03-31 | Ex-US | KSPHF | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration |
| 2027-03-31 | Ex-US | MSCLF | Satellos Bioscience Inc. | Phase 2 | Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients |
| 2027-03-31 | US | ADCT | ADC Therapeutics SA | Phase 1 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) |
| 2027-03-31 | US | ALT | Altimmune, Inc. | Phase 2 | RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) |
| 2027-03-31 | US | CGON | CG Oncology, Inc. | Phase 2 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC |
| 2027-03-31 | US | STJO | St. Joseph, Inc. | Phase 2 | Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine |
| 2027-03-31 | US | TNGX | Tango Therapeutics, Inc. | Phase 1/Phase 2 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss |
| 2027-03-31 | US | HURA | TuHURA Biosciences, Inc. | Phase 2/Phase 3 | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma |
| 2027-04 | EU | ZEAL
XCSE | Zealand Pharma | Phase 1 | A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period |
| 2027-04 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1/Phase 2 | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease |
| 2027-04 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer |
| 2027-04 | Ex-US | ZLDPF | Zealand Pharma A/S | Phase 1 | A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period |
| 2027-04 | US | ABCL | AbCellera Biologics Inc. | Phase 1 | A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants |
| 2027-04 | US | CLYM | Climb Bio Inc | Phase 1 | A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) |
| 2027-04 | US | CGTX | Cognition Therapeutics, Inc. | Phase 2 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer’s Disease |
| 2027-04 | US | IXHL | Incannex Healthcare Inc. | Phase 2 | DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea. |
| 2027-04 | US | KPTI | Karyopharm Therapeutics Inc. | Phase 1/Phase 2 | Selinexor and Backbone Treatments of Multiple Myeloma Patients |
| 2027-04 | US | KOD | Kodiak Sciences Inc. | Phase 3 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) – PEAK |
| 2027-04 | US | KYTX | Kyverna Therapeutics, Inc. | Phase 2 | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis |
| 2027-04 | US | MIRM | Mirum Pharmaceuticals, Inc. | Phase 2 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis |
| 2027-04 | US | NKTX | Nkarta, Inc. | Phase 1/Phase 2 | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) |
| 2027-04 | US | RAPT | RAPT Therapeutics, Inc. | Phase 2 | Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy |
| 2027-04 | US | VTVT | vTv Therapeutics Inc. | Phase 2 | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems |
| 2027-04 | US | VTVT | vTv Therapeutics Inc. | Phase 3 | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes |
| 2027-04 | US | XENE | Xenon Pharmaceuticals Inc. | Phase 3 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures |
| 2027-04-01 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 1/Phase 2 | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors |
| 2027-04-01 | US | ASRT | Assertio Holdings, Inc. | Phase 1/Phase 2 | Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease |
| 2027-04-01 | US | TLSA | Tiziana Life Sciences Ltd | Phase 2 | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) |
| 2027-04-12 | EU | ZEAL
XCSE | Zealand Pharma | Phase 1 | Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function |
| 2027-04-12 | Ex-US | ZLDPF | Zealand Pharma A/S | Phase 1 | Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function |
| 2027-04-24 | US | ZJYL | Jin Medical International Ltd. | Phase 2 | Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13） |
| 2027-04-25 | EU | ALM*
XMAD | Almirall | Phase 3 | A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis |
| 2027-04-25 | Ex-US | ALMRY | Almirall SA | Phase 3 | A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis |
| 2027-04-25 | Ex-US | LBTSF | Almirall, S.A. | Phase 3 | A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis |
| 2027-04-25 | US | PYXS | Pyxis Oncology, Inc. | Phase 1 | A Study of PYX-201 in Advanced Solid Tumors |
| 2027-04-26 | US | TLX | Telix Pharmaceuticals Limited | Phase 1 | Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain |
| 2027-04-30 | EU | ARGX
XBRU | argenx | Phase 2 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) |
| 2027-04-30 | EU | NANO
XPAR | Nanobiotix | Phase 1 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
| 2027-04-30 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome |
| 2027-04-30 | Ex-US | NPPNY | Nippon Shinyaku Co., Ltd. | Phase 2 | Extension Study of NS-089/NCNP-02 in DMD |
| 2027-04-30 | US | RNA | Avidity Biosciences, Inc. | Phase 2 | Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping |
| 2027-04-30 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 2 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma |
| 2027-04-30 | US | NBTX | Nanobiotix S.A. | Phase 1 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
| 2027-04-30 | US | RLAY | Relay Therapeutics, Inc. | Phase 1 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer |
| 2027-05 | EU | VICO
XSTO | Vicore Pharma | Phase 2 | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. |
| 2027-05 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 1 | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST |
| 2027-05 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC |
| 2027-05 | US | RCUS | Arcus Biosciences, Inc. | Phase 1 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies |
| 2027-05 | US | RCUS | Arcus Biosciences, Inc. | Phase 1 | Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function |
| 2027-05 | US | RCUS | Arcus Biosciences, Inc. | Phase 2 | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer |
| 2027-05 | US | BOLT | Bolt Biotherapeutics, Inc. | Phase 1/Phase 2 | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer |
| 2027-05 | US | IRON | Disc Medicine, Inc. | Phase 1/Phase 2 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia |
| 2027-05 | US | JBIO | Jade Biosciences, Inc. | Phase 1 | A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants |
| 2027-05 | US | STJO | St. Joseph, Inc. | Phase 2 | Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia |
| 2027-05 | US | VXRT | Vaxart, Inc. | Phase 2 | A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection |
| 2027-05 | US | VYGR | Voyager Therapeutics, Inc. | Phase 1/Phase 2 | VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer’s Disease |
| 2027-05 | US | XNCR | Xencor, Inc. | Phase 1 | Study of XmAb412 in Healthy Participants |
| 2027-05 | US | XENE | Xenon Pharmaceuticals Inc. | Phase 3 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) |
| 2027-05 | US | ZURA | Zura Bio Limited | Phase 2 | Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) |
| 2027-05-01 | Ex-US | ABSCF | AB Science S.A. | Phase 3 | Tele-Collaborative Outreach to Rural Patients With Chronic Pain |
| 2027-05-01 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | App for Reducing Cravings to Smoke |
| 2027-05-05 | US | FTRE | Fortrea Holdings Inc. | Phase 1 | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. |
| 2027-05-06 | US | SLDB | Solid Biosciences Inc. | Phase 1/Phase 2 | A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) |
| 2027-05-25 | EU | ALM*
XMAD | Almirall | Phase 2 | A Study of LAD191 in Adults With Hidradenitis Suppurativa |
| 2027-05-25 | Ex-US | ALMRY | Almirall SA | Phase 2 | A Study of LAD191 in Adults With Hidradenitis Suppurativa |
| 2027-05-25 | Ex-US | LBTSF | Almirall, S.A. | Phase 2 | A Study of LAD191 in Adults With Hidradenitis Suppurativa |
| 2027-05-26 | US | FDMT | 4D Molecular Therapeutics, Inc. | Phase 1 | Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia |
| 2027-05-27 | US | MBX | MBX Biosciences, Inc. | Phase 2 | Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism |
| 2027-05-30 | Ex-US | ABSCF | AB Science S.A. | Phase 2 | Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis |
| 2027-05-30 | US | ACRV | Acrivon Therapeutics, Inc. | Phase 2 | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma |
| 2027-05-30 | US | OLMA | Olema Pharmaceuticals, Inc. | Phase 1 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors |
| 2027-05-30 | US | TGTX | TG Therapeutics, Inc. | Phase 2 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) |
| 2027-05-30 | US | ZLAB | Zai Lab Limited | Phase 1 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer |
| 2027-05-31 | EU | ALM*
XMAD | Almirall | Phase 1 | A Study of LAD106 in Healthy Adult Participants |
| 2027-05-31 | Ex-US | ABSCF | AB Science S.A. | Phase 2 | Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC |
| 2027-05-31 | Ex-US | ALMRY | Almirall SA | Phase 1 | A Study of LAD106 in Healthy Adult Participants |
| 2027-05-31 | Ex-US | LBTSF | Almirall, S.A. | Phase 1 | A Study of LAD106 in Healthy Adult Participants |
| 2027-05-31 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | A Trial of Lu AF28996 in Participants With Parkinson’s Disease (PD) |
| 2027-05-31 | US | DAWN | Day One Biopharmaceuticals, Inc. | Phase 2 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors |
| 2027-05-31 | US | SRPT | Sarepta Therapeutics, Inc. | Phase 3 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) |
| 2027-06 | EU | BSLN
XSWX | Basilea Pharmaceutica | Phase 1 | A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects |
| 2027-06 | EU | ALBPS
XPAR | Biophytis | Phase 2 | Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. |
| 2027-06 | EU | GMAB
XCSE | Genmab | Phase 3 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
| 2027-06 | EU | IDIA
XSWX | Idorsia | Phase 2 | A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo |
| 2027-06 | EU | IPH
XPAR | Innate Pharma | Phase 2 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) |
| 2027-06 | Ex-US | CHIZF | China Traditional Chinese Medicine Holdings Co. Limited | Phase 3 | Study of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome |
| 2027-06 | Ex-US | IDRSF | Idorsia Ltd | Phase 2 | A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo |
| 2027-06 | Ex-US | IUGNF | Imugene Limited | Phase 1 | Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) |
| 2027-06 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 1 | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies |
| 2027-06 | Ex-US | SOLTF | Nxera Pharma Co., Ltd. | Phase 1/Phase 2 | HTL0039732 in Participants With Advanced Solid Tumours |
| 2027-06 | US | FDMT | 4D Molecular Therapeutics, Inc. | Phase 2 | 4D-710 in Adult Patients With Cystic Fibrosis |
| 2027-06 | US | FDMT | 4D Molecular Therapeutics, Inc. | Phase 3 | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration |
| 2027-06 | US | AKBA | Akebia Therapeutics, Inc. | Phase 2 | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) |
| 2027-06 | US | ALXO | ALX Oncology Holdings Inc. | Phase 1 | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors |
| 2027-06 | US | APRE | Aprea Therapeutics, Inc. | Phase 1 | Study of APR-1051 in Patients With Advanced Solid Tumors |
| 2027-06 | US | BLLN | BillionToOne, Inc. | Phase 1 | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) |
| 2027-06 | US | BMEA | Biomea Fusion, Inc. | Phase 2 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy |
| 2027-06 | US | CRVS | Corvus Pharmaceuticals, Inc. | Phase 2 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD |
| 2027-06 | US | DAWN | Day One Biopharmaceuticals, Inc. | Phase 3 | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) |
| 2027-06 | US | DNLI | Denali Therapeutics Inc. | Phase 2/Phase 3 | An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 |
| 2027-06 | US | IRON | Disc Medicine, Inc. | Phase 1 | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) |
| 2027-06 | US | HUMA | Humacyte, Inc. | Phase 3 | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis |
| 2027-06 | US | IMMP | Immutep Limited | Phase 3 | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) |
| 2027-06 | US | IPHA | Innate Pharma S.A. | Phase 2 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) |
| 2027-06 | US | KPTI | Karyopharm Therapeutics Inc. | Phase 2 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
| 2027-06 | US | LNTH | Lantheus Holdings, Inc. | Phase 3 | [18F]PI-2620 Phase 3 Histopathological Study |
| 2027-06 | US | LBRX | LB Pharmaceuticals Inc. | Phase 3 | Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia |
| 2027-06 | US | MGTX | MeiraGTx Holdings plc | Phase 2 | A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia |
| 2027-06 | US | NMRA | Neumora Therapeutics, Inc. | Phase 3 | Study to Assess the Safety and Effectiveness of NMRA-335140-501 |
| 2027-06 | US | ORIC | ORIC Pharmaceuticals, Inc. | Phase 1 | Study of ORIC-944 in Patients With Metastatic Prostate Cancer |
| 2027-06 | US | ORKA | Oruka Therapeutics, Inc. | Phase 2 | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis |
| 2027-06 | US | PHVS | Pharvaris N.V. | Phase 2/Phase 3 | Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema |
| 2027-06 | US | PHVS | Pharvaris N.V. | Phase 3 | Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency |
| 2027-06 | US | TARA | Protara Therapeutics, Inc. | Phase 2/Phase 3 | Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support |
| 2027-06 | US | RXRX | Recursion Pharmaceuticals, Inc. | Phase 1/Phase 2 | Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) |
| 2027-06 | US | SVRA | Savara Inc. | Phase 3 | Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). |
| 2027-06 | US | SNSE | Sensei Biotherapeutics, Inc. | Phase 1/Phase 2 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors |
| 2027-06 | US | SLDB | Solid Biosciences Inc. | Phase 1 | A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) |
| 2027-06 | US | SYRE | Spyre Therapeutics, Inc. | Phase 2 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis |
| 2027-06 | US | TNGX | Tango Therapeutics, Inc. | Phase 1/Phase 2 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients |
| 2027-06 | US | VSTM | Verastem, Inc. | Phase 2 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer |
| 2027-06 | US | VSTM | Verastem, Inc. | Phase 2 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer |
| 2027-06 | US | VSTM | Verastem, Inc. | Phase 2 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer |
| 2027-06 | US | VRCA | Verrica Pharmaceuticals Inc. | Phase 3 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) |
| 2027-06-01 | US | EIKN | Eikon Therapeutics, Inc. | Phase 1/Phase 2 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors |
| 2027-06-01 | US | MIST | Milestone Pharmaceuticals Inc. | Phase 2 | The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) |
| 2027-06-09 | US | IOBT | IO Biotech, Inc. | Phase 2 | A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma |
| 2027-06-15 | Ex-US | CRTHF | CARsgen Therapeutics Holdings Limited | Phase 1/Phase 2 | Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL |
| 2027-06-23 | EU | ALM*
XMAD | Almirall | Phase 2 | A Study of LAD603 in Adults With Alopecia Areata |
| 2027-06-23 | Ex-US | ALMRY | Almirall SA | Phase 2 | A Study of LAD603 in Adults With Alopecia Areata |
| 2027-06-23 | Ex-US | LBTSF | Almirall, S.A. | Phase 2 | A Study of LAD603 in Adults With Alopecia Areata |
| 2027-06-25 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 1 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies |
| 2027-06-25 | US | APLS | Apellis Pharmaceuticals, Inc. | Phase 2 | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio |
| 2027-06-25 | US | FTRE | Fortrea Holdings Inc. | Phase 3 | Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. |
| 2027-06-30 | Ex-US | ABSCF | AB Science S.A. | Phase 3 | Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis |
| 2027-06-30 | Ex-US | CSPHF | CStone Pharmaceuticals | Phase 1 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas |
| 2027-06-30 | Ex-US | JBPHF | Jacobio Pharmaceuticals Group Co., Ltd. | Phase 2 | A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis |
| 2027-06-30 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer |
| 2027-06-30 | US | CNTA | Centessa Pharmaceuticals plc | Phase 1 | A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years |
| 2027-06-30 | US | IMNN | Imunon, Inc. | Phase 1/Phase 2 | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| 2027-06-30 | US | INDP | Indaptus Therapeutics, Inc. | Phase 1/Phase 2 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors |
| 2027-06-30 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma |
| 2027-06-30 | US | MIRM | Mirum Pharmaceuticals, Inc. | Phase 3 | A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) |
| 2027-07 | EU | ARGX
XBRU | argenx | Phase 3 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren’s Syndrome |
| 2027-07 | EU | GMAB
XCSE | Genmab | Phase 1/Phase 2 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) |
| 2027-07 | EU | ALSEN
XPAR | Sensorion | Phase 1/Phase 2 | A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations |
| 2027-07 | Ex-US | PBIGF | Paradigm Biopharmaceuticals Limited | Phase 3 | A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. |
| 2027-07 | US | ANL | Adlai Nortye Ltd. | Phase 1 | An Initial Evaluation of AN8025 in Solid Tumors |
| 2027-07 | US | FOLD | Amicus Therapeutics, Inc. | Phase 3 | A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 |
| 2027-07 | US | APLS | Apellis Pharmaceuticals, Inc. | Phase 3 | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
| 2027-07 | US | BHVN | Biohaven Ltd. | Phase 1 | Study of BHV-1400 in IgA Nephropathy |
| 2027-07 | US | NTLA | Intellia Therapeutics, Inc. | Phase 3 | A Phase 3 Study of NTLA-2001 in ATTRv-PN |
| 2027-07 | US | JANX | Janux Therapeutics, Inc. | Phase 1 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) |
| 2027-07 | US | MGNX | MacroGenics, Inc. | Phase 2 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors |
| 2027-07 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma |
| 2027-07 | US | MESO | Mesoblast Limited | Phase 3 | Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain |
| 2027-07 | US | SGMO | Sangamo Therapeutics, Inc. | Phase 1/Phase 2 | Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) |
| 2027-07 | US | TLX | Telix Pharmaceuticals Limited | Phase 3 | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma |
| 2027-07 | US | TLSA | Tiziana Life Sciences Ltd | Phase 2 | The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab |
| 2027-07 | US | ZVRA | Zevra Therapeutics, Inc. | Phase 1 | An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA) |
| 2027-07-01 | US | STJO | St. Joseph, Inc. | Phase 1 | Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease |
| 2027-07-01 | US | VKTX | Viking Therapeutics, Inc. | Phase 3 | VK2735 for Weight Management Phase 3 |
| 2027-07-01 | US | VKTX | Viking Therapeutics, Inc. | Phase 3 | VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) |
| 2027-07-06 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 3 | A Study of Eptinezumab in Pediatric Participants With Episodic Migraine |
| 2027-07-30 | EU | GMAB
XCSE | Genmab | Phase 3 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) |
| 2027-07-30 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 1 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types |
| 2027-07-30 | US | ONCY | Oncolytics Biotech Inc. | Phase 1/Phase 2 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
| 2027-07-31 | US | BTAI | BioXcel Therapeutics, Inc. | Phase 1 | Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder |
| 2027-07-31 | US | MAIA | MAIA Biotechnology, Inc. | Phase 3 | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC |
| 2027-08 | EU | GNFT
XPAR | Genfit | Phase 2 | Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure |
| 2027-08 | EU | GMAB
XCSE | Genmab | Phase 1 | A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors |
| 2027-08 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 3 | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. |
| 2027-08 | US | ACAD | ACADIA Pharmaceuticals Inc. | Phase 2 | ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response |
| 2027-08 | US | ARTV | Artiva Biotherapeutics, Inc. | Phase 1 | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus |
| 2027-08 | US | BHVN | Biohaven Ltd. | Phase 2/Phase 3 | A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson’s Disease |
| 2027-08 | US | BBOT | BridgeBio Oncology Therapeutics, Inc. | Phase 1 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer |
| 2027-08 | US | CLLS | Cellectis S.A. | Phase 1/Phase 2 | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma |
| 2027-08 | US | CLYM | Climb Bio Inc | Phase 1/Phase 2 | A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) |
| 2027-08 | US | KPRX | Kiora Pharmaceuticals, Inc. | Phase 2 | A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa |
| 2027-08 | US | LNTH | Lantheus Holdings, Inc. | Phase 1/Phase 2 | Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) |
| 2027-08 | US | SUPN | Supernus Pharmaceuticals, Inc. | Phase 2 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures |
| 2027-08 | US | TNYA | Tenaya Therapeutics, Inc. | Phase 1/Phase 2 | Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM |
| 2027-08 | US | TVTX | Travere Therapeutics, Inc. | Phase 3 | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment |
| 2027-08 | US | RARE | Ultragenyx Pharmaceutical Inc. | Phase 3 | A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD |
| 2027-08 | US | RARE | Ultragenyx Pharmaceutical Inc. | Phase 3 | Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA |
| 2027-08 | US | VRCA | Verrica Pharmaceuticals Inc. | Phase 3 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) |
| 2027-08 | US | ZLAB | Zai Lab Limited | Phase 1/Phase 2 | A Study of ZL-1310 in Participants With Selected Solid Tumors |
| 2027-08-01 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma |
| 2027-08-01 | US | ZJYL | Jin Medical International Ltd. | Phase 2 | Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia |
| 2027-08-01 | US | VSTM | Verastem, Inc. | Phase 2 | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) |
| 2027-08-10 | US | LCTX | Lineage Cell Therapeutics, Inc. | Phase 1 | A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury |
| 2027-08-16 | US | VIR | Vir Biotechnology, Inc. | Phase 1/Phase 2 | To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers |
| 2027-08-24 | EU | ARGX
XBRU | argenx | Phase 1 | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) |
| 2027-08-30 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer |
| 2027-08-30 | US | ONCY | Oncolytics Biotech Inc. | Phase 2 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer |
| 2027-08-30 | US | RADX | Radiopharm Theranostics Limited | Phase 1 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. |
| 2027-08-31 | US | CANF | Can-Fite BioPharma Ltd. | Phase 2 | An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome |
| 2027-08-31 | US | IART | Integra LifeSciences Holdings Corporation | Phase 2 | Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy |
| 2027-08-31 | US | MIRM | Mirum Pharmaceuticals, Inc. | Phase 2/Phase 3 | Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide |
| 2027-08-31 | US | TLX | Telix Pharmaceuticals Limited | Phase 3 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC |
| 2027-09 | EU | ARGX
XBRU | argenx | Phase 3 | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP |
| 2027-09 | EU | GMAB
XCSE | Genmab | Phase 1/Phase 2 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) |
| 2027-09 | EU | GMAB
XCSE | Genmab | Phase 3 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer in China |
| 2027-09 | EU | NYKD
XOSL | Nykode Therapeutics | Phase 1/Phase 2 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma |
| 2027-09 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC |
| 2027-09 | Ex-US | VACBF | Nykode Therapeutics AS | Phase 1/Phase 2 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma |
| 2027-09 | US | AGEN | Agenus Inc. | Phase 2 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer |
| 2027-09 | US | RCUS | Arcus Biosciences, Inc. | Phase 1 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
| 2027-09 | US | BHVN | Biohaven Ltd. | Phase 1 | Study of BHV-1300 in Graves’ Disease |
| 2027-09 | US | CSTL | Castle Biosciences, Inc. | Phase 3 | Evaluation of D-Fi for the Treatment of Wounds Due to DEB |
| 2027-09 | US | CLYM | Climb Bio Inc | Phase 1/Phase 2 | A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) |
| 2027-09 | US | CHRS | Coherus Oncology, Inc. | Phase 2 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma |
| 2027-09 | US | CORT | Corcept Therapeutics Incorporated | Phase 2 | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma |
| 2027-09 | US | IMTX | Immatics N.V. | Phase 1/Phase 2 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors |
| 2027-09 | US | IOVA | Iovance Biotherapeutics, Inc. | Phase 1/Phase 2 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer |
| 2027-09 | US | KYTX | Kyverna Therapeutics, Inc. | Phase 2/Phase 3 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis |
| 2027-09 | US | NEO | NeoGenomics, Inc. | Phase 2 | Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC |
| 2027-09 | US | OPK | OPKO Health, Inc. | Phase 1 | A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19. |
| 2027-09 | US | KTTA | Pasithea Therapeutics Corp. | Phase 1 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas |
| 2027-09 | US | RZLT | Rezolute, Inc. | Phase 3 | A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism |
| 2027-09 | US | STJO | St. Joseph, Inc. | Phase 2 | Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET |
| 2027-09 | US | TLSI | TriSalus Life Sciences, Inc. | Phase 1 | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma |
| 2027-09 | US | RARE | Ultragenyx Pharmaceutical Inc. | Phase 3 | Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency |
| 2027-09 | US | UPB | Upstream Bio, Inc. | Phase 2 | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) |
| 2027-09 | US | XFOR | X4 Pharmaceuticals, Inc. | Phase 3 | A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections |
| 2027-09 | US | ZYME | Zymeworks Inc. | Phase 1 | A Study of ZW251 in Participants With Advanced Solid Tumors |
| 2027-09-29 | US | VIR | Vir Biotechnology, Inc. | Phase 1 | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer |
| 2027-09-30 | EU | GMAB
XCSE | Genmab | Phase 1/Phase 2 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) |
| 2027-09-30 | EU | IVA
XPAR | Inventiva | Phase 3 | A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) |
| 2027-09-30 | US | CNTA | Centessa Pharmaceuticals plc | Phase 2/Phase 3 | A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence |
| 2027-09-30 | US | CGEM | Cullinan Therapeutics, Inc. | Phase 1 | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients |
| 2027-09-30 | US | FATE | Fate Therapeutics, Inc. | Phase 1 | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease |
| 2027-09-30 | US | IMCR | Immunocore Holdings plc | Phase 1 | Study of IMC-P115C in Advanced PRAME-Positive Cancers |
| 2027-09-30 | US | MAIA | MAIA Biotechnology, Inc. | Phase 2 | THIO Sequenced With Cemiplimab in Advanced NSCLC |
| 2027-09-30 | US | RNTX | Rein Therapeutics Inc. | Phase 2 | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis |
| 2027-09-30 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 3 | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness |
| 2027-10 | EU | ARGX
XBRU | argenx | Phase 2 | ADAPT Forward 2 – ISA2 – a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis |
| 2027-10 | EU | PHARM
XAMS | Pharming | Phase 2 | Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease |
| 2027-10 | US | APVO | Aptevo Therapeutics Inc. | Phase 1 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML |
| 2027-10 | US | CLYM | Climb Bio Inc | Phase 2 | A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy |
| 2027-10 | US | EVMN | Evommune, Inc. | Phase 2 | Study of EVO756 in Adults With Migraine |
| 2027-10 | US | EYPT | EyePoint, Inc. | Phase 3 | CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME |
| 2027-10 | US | EYPT | EyePoint, Inc. | Phase 3 | COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME |
| 2027-10 | US | HRMY | Harmony Biosciences Holdings, Inc. | Phase 3 | A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) |
| 2027-10 | US | HRMY | Harmony Biosciences Holdings, Inc. | Phase 3 | A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy |
| 2027-10 | US | JBIO | Jade Biosciences, Inc. | Phase 1 | A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis |
| 2027-10 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors |
| 2027-10 | US | MIRM | Mirum Pharmaceuticals, Inc. | Phase 2 | Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) |
| 2027-10 | US | OPK | OPKO Health, Inc. | Phase 2 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants |
| 2027-10 | US | ORKA | Oruka Therapeutics, Inc. | Phase 2 | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis |
| 2027-10 | US | PHAR | Pharming Group N.V. | Phase 2 | Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease |
| 2027-10 | US | UPB | Upstream Bio, Inc. | Phase 2 | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD |
| 2027-10-01 | Ex-US | ABSCF | AB Science S.A. | Phase 2 | Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis |
| 2027-10-01 | US | CERS | Cerus Corporation | Phase 2 | Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs |
| 2027-10-07 | EU | ARGX
XBRU | argenx | Phase 3 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP |
| 2027-10-11 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML |
| 2027-10-15 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma |
| 2027-10-16 | US | IMCR | Immunocore Holdings plc | Phase 3 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) |
| 2027-10-20 | Ex-US | KNTPF | Kintor Pharmaceutical Limited | Phase 2/Phase 3 | To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia |
| 2027-10-20 | US | PHAT | Phathom Pharmaceuticals, Inc. | Phase 3 | A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks |
| 2027-10-22 | US | MJNA | Medical Marijuana, Inc. | Phase 3 | Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder |
| 2027-10-26 | Ex-US | GSGTF | GenSight Biologics S.A. | Phase 1/Phase 2 | Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa |
| 2027-10-30 | US | PBYI | Puma Biotechnology, Inc. | Phase 2 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer |
| 2027-10-30 | US | TFX | Teleflex Incorporated | Phase 1 | Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies |
| 2027-10-31 | Ex-US | JCRRF | JCR Pharmaceuticals Co., Ltd. | Phase 3 | A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT) |
| 2027-10-31 | Ex-US | NURPF | Neuren Pharmaceuticals Limited | Phase 3 | A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome |
| 2027-10-31 | US | CUE | Cue Biopharma, Inc. | Phase 2 | Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma |
| 2027-10-31 | US | LXRX | Lexicon Pharmaceuticals, Inc. | Phase 2 | Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes |
| 2027-11 | EU | ARGX
XBRU | argenx | Phase 2 | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) |
| 2027-11 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | BCL2i CLAG-M in R/R Acute Myeloid Leukemia |
| 2027-11 | Ex-US | JBPHF | Jacobio Pharmaceuticals Group Co., Ltd. | Phase 1/Phase 2 | JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration |
| 2027-11 | Ex-US | KSPHF | Kissei Pharmaceutical Co., Ltd. | Phase 3 | A Clinical Study of KLH-2109 in Patients With Endometriosis |
| 2027-11 | US | ANRO | Alto Neuroscience, Inc. | Phase 2 | ALTO-207 in Adults With Treatment-resistant Depression (TRD) |
| 2027-11 | US | RNAC | Cartesian Therapeutics, Inc. | Phase 2 | Descartes-08 in Autoantibody Myositis |
| 2027-11 | US | CRVS | Corvus Pharmaceuticals, Inc. | Phase 3 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma |
| 2027-11 | US | CRIS | Curis, Inc. | Phase 2 | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies |
| 2027-11 | US | DVAX | Dynavax Technologies Corporation | Phase 1/Phase 2 | Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over |
| 2027-11 | US | MPLT | MapLight Therapeutics, Inc. | Phase 2 | ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) |
| 2027-11 | US | NAMS | NewAmsterdam Pharma Company N.V. | Phase 3 | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque |
| 2027-11 | US | SABS | SAB Biotherapeutics, Inc. | Phase 2 | SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes |
| 2027-11 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 3 | Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia |
| 2027-11 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 3 | Randomized Withdrawal Study in Patients With Schizophrenia |
| 2027-11 | US | VERA | Vera Therapeutics, Inc. | Phase 2 | Atacicept in Multiple Glomerular Diseases |
| 2027-11-01 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 1/Phase 2 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial |
| 2027-11-12 | EU | ZEAL
XCSE | Zealand Pharma | Phase 2
partner: Roche | A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight |
| 2027-11-15 | US | AURA | Aura Biosciences, Inc. | Phase 3 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma |
| 2027-11-22 | EU | GMAB
XCSE | Genmab | Phase 2 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer |
| 2027-11-22 | US | CGEN | Compugen Ltd. | Phase 1 | A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies |
| 2027-11-30 | EU | FARON*
XHEL | Faron Pharmaceuticals | Phase 2 | Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes |
| 2027-11-30 | Ex-US | FGHQF | Frontage Holdings Corporation | Phase 2 | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors |
| 2027-11-30 | US | ARVN | Arvinas, Inc. | Phase 1/Phase 2 | A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation |
| 2027-11-30 | US | CTMX | CytomX Therapeutics, Inc. | Phase 1 | First In Human Study of CX-2051 in Advanced Solid Tumors |
| 2027-11-30 | US | MYGN | Myriad Genetics, Inc. | Phase 2 | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors |
| 2027-11-30 | US | SRPT | Sarepta Therapeutics, Inc. | Phase 1 | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington’s Disease |
| 2027-12 | EU | GNFT
XPAR | Genfit | Phase 1/Phase 2 | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma |
| 2027-12 | EU | GMAB
XCSE | Genmab | Phase 1/Phase 2 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome |
| 2027-12 | EU | PHIL
XMIL | Philogen | Phase 1 | A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer |
| 2027-12 | EU | PHIL
XMIL | Philogen | Phase 3 | Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients |
| 2027-12 | Ex-US | ABSCF | AB Science S.A. | Phase 2 | Pembrolizumab + MRGOO3 as Neoadjuvant in NPC |
| 2027-12 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 1 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors |
| 2027-12 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 1 | APG-2449 in Patients With Advanced Solid Tumors |
| 2027-12 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Methylphenidate for Apathy in Veterans With Parkinson’s Disease |
| 2027-12 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 2 | A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) |
| 2027-12 | US | AKTS | Aktis Oncology, Inc. | Phase 1 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors |
| 2027-12 | US | AKTS | Aktis Oncology, Inc. | Phase 1 | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer |
| 2027-12 | US | ALLO | Allogene Therapeutics, Inc. | Phase 2 | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL |
| 2027-12 | US | ALXO | ALX Oncology Holdings Inc. | Phase 2 | ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer |
| 2027-12 | US | FOLD | Amicus Therapeutics, Inc. | Phase 3 | A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants |
| 2027-12 | US | ANTX | AN2 Therapeutics, Inc. | Phase 2 | Epetraborole in Patients With Mycobacterium Abscessus Lung Disease |
| 2027-12 | US | ANVS | Annovis Bio, Inc. | Phase 3 | A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD |
| 2027-12 | US | BCTX | BriaCell Therapeutics Corp. | Phase 3 | Study of the Bria-IMT Regimen and CPI vs Physicians’ Choice in Advanced Metastatic Breast Cancer. |
| 2027-12 | US | CANF | Can-Fite BioPharma Ltd. | Phase 3 | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy |
| 2027-12 | US | CRBU | Caribou Biosciences, Inc. | Phase 1 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma |
| 2027-12 | US | RNAC | Cartesian Therapeutics, Inc. | Phase 1/Phase 2 | Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders |
| 2027-12 | US | DAWN | Day One Biopharmaceuticals, Inc. | Phase 1 | To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors |
| 2027-12 | US | DNLI | Denali Therapeutics Inc. | Phase 2/Phase 3 | A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) |
| 2027-12 | US | EWTX | Edgewise Therapeutics, Inc. | Phase 2 | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) |
| 2027-12 | US | ELVN | Enliven Therapeutics, Inc. | Phase 1 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia |
| 2027-12 | US | GOSS | Gossamer Bio, Inc. | Phase 2 | Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) |
| 2027-12 | US | NTLA | Intellia Therapeutics, Inc. | Phase 3 | MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) |
| 2027-12 | US | INTS | Intensity Therapeutics, Inc. | Phase 3 | A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) |
| 2027-12 | US | KURA | Kura Oncology, Inc. | Phase 1 | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) |
| 2027-12 | US | LEGN | Legend Biotech Corporation | Phase 1 | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma |
| 2027-12 | US | LEGN | Legend Biotech Corporation | Phase 1 | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer |
| 2027-12 | US | MPLT | MapLight Therapeutics, Inc. | Phase 2 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer’s Disease Psychosis |
| 2027-12 | US | MAZE | Maze Therapeutics, Inc. | Phase 2 | A Study of MZE782 in Adults With PKU |
| 2027-12 | US | NUVL | Nuvalent, Inc. | Phase 1/Phase 2 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) |
| 2027-12 | US | OPK | OPKO Health, Inc. | Phase 1/Phase 2 | Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants |
| 2027-12 | US | RADX | Radiopharm Theranostics Limited | Phase 1/Phase 2 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors |
| 2027-12 | US | RPTX | Repare Therapeutics Inc. | Phase 1 | Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors |
| 2027-12 | US | SANA | Sana Biotechnology, Inc. | Phase 1 | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) |
| 2027-12 | US | STJO | St. Joseph, Inc. | Phase 2 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) |
| 2027-12 | US | STRO | Sutro Biopharma, Inc. | Phase 1 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer |
| 2027-12 | US | TLX | Telix Pharmaceuticals Limited | Phase 3 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) |
| 2027-12 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 1 | Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies |
| 2027-12 | US | WVE | Wave Life Sciences Ltd. | Phase 1/Phase 2 | A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity |
| 2027-12 | US | XNCR | Xencor, Inc. | Phase 1 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors |
| 2027-12-01 | Ex-US | MDGEF | Medigene AG | Phase 1 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma |
| 2027-12-01 | US | ALMS | Alumis Inc. | Phase 2 | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis |
| 2027-12-01 | US | ZJYL | Jin Medical International Ltd. | Phase 2 | Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer |
| 2027-12-01 | US | REPL | Replimune, Inc. | Phase 2 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC |
| 2027-12-01 | US | TGTX | TG Therapeutics, Inc. | Phase 1 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders |
| 2027-12-01 | US | TGTX | TG Therapeutics, Inc. | Phase 3 | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab |
| 2027-12-01 | US | QURE | uniQure N.V. | Phase 1/Phase 2 | Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease |
| 2027-12-02 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 1 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia |
| 2027-12-06 | US | PYXS | Pyxis Oncology, Inc. | Phase 1/Phase 2 | Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors |
| 2027-12-15 | EU | OSE
XPAR | OSE Immunotherapeutics | Phase 3 | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor |
| 2027-12-15 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System |
| 2027-12-15 | Ex-US | ORPOF | OSE IMMUNOTHERAPEUTICS | Phase 3 | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor |
| 2027-12-15 | US | SNDX | Syndax Pharmaceuticals, Inc. | Phase 1/Phase 2 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation |
| 2027-12-20 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer |
| 2027-12-25 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 1/Phase 2 | Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors |
| 2027-12-28 | US | ZLAB | Zai Lab Limited | Phase 1 | A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis |
| 2027-12-30 | EU | TNG
XPAR | Transgene | Phase 1/Phase 2 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer |
| 2027-12-30 | Ex-US | TRGNF | Transgene SA | Phase 1/Phase 2 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer |
| 2027-12-30 | US | BEAM | Beam Therapeutics Inc. | Phase 1/Phase 2 | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) |
| 2027-12-30 | US | CGEM | Cullinan Therapeutics, Inc. | Phase 1 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis |
| 2027-12-30 | US | MDWD | MediWound Ltd. | Phase 2 | Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers |
| 2027-12-30 | US | PBYI | Puma Biotechnology, Inc. | Phase 2 | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer |
| 2027-12-30 | US | RLAY | Relay Therapeutics, Inc. | Phase 1 | A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors |
| 2027-12-31 | EU | ORNBV
XHEL | Orion Corporation | Phase 1/Phase 2 | A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours |
| 2027-12-31 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918. |
| 2027-12-31 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 3 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) |
| 2027-12-31 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 1 | Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation |
| 2027-12-31 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Mammogram Pretreatment With Ulipristal Acetate |
| 2027-12-31 | Ex-US | LYPHF | Luye Pharma Group Ltd. | Phase 2 | A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia |
| 2027-12-31 | Ex-US | LYPHF | Luye Pharma Group Ltd. | Phase 3 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC |
| 2027-12-31 | US | KNSA | Kiniksa Pharmaceuticals International, plc | Phase 2 | Transition to KPL-387 Monotherapy Dosing & Administration Study |
| 2027-12-31 | US | KNSA | Kiniksa Pharmaceuticals International, plc | Phase 2/Phase 3 | Phase 2/3 Study of KPL-387 in Recurrent Pericarditis |
| 2027-12-31 | US | MJNA | Medical Marijuana, Inc. | Phase 1 | Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease |
| 2027-12-31 | US | NUVL | Nuvalent, Inc. | Phase 1/Phase 2 | A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) |
| 2027-12-31 | US | OLMA | Olema Pharmaceuticals, Inc. | Phase 1 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer |
| 2027-12-31 | US | CATX | Perspective Therapeutics, Inc. | Phase 1/Phase 2 | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma |
| 2027-12-31 | US | SRPT | Sarepta Therapeutics, Inc. | Phase 1 | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) – Non-Ambulatory Cohort |
| 2027-12-31 | US | STJO | St. Joseph, Inc. | Phase 2 | Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. |
| 2027-12-31 | US | SUPN | Supernus Pharmaceuticals, Inc. | Phase 2 | Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy |
| 2027-12-31 | US | SUPN | Supernus Pharmaceuticals, Inc. | Phase 2 | SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures |
| 2028-01 | Ex-US | CSPHF | CStone Pharmaceuticals | Phase 1 | A Phase I Study of CS5007 in Participants With Advanced Solid Tumors |
| 2028-01 | Ex-US | JBPHF | Jacobio Pharmaceuticals Group Co., Ltd. | Phase 1/Phase 2 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors |
| 2028-01 | US | ACIU | AC Immune SA | Phase 2 | A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson’s Disease |
| 2028-01 | US | ACAD | ACADIA Pharmaceuticals Inc. | Phase 2/Phase 3 | ACP-204 in Adults With Alzheimer’s Disease Psychosis |
| 2028-01 | US | ARTV | Artiva Biotherapeutics, Inc. | Phase 2 | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. |
| 2028-01 | US | BHVN | Biohaven Ltd. | Phase 3 | Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves’ Disease |
| 2028-01 | US | BLRX | BioLineRx Ltd. | Phase 1 | SCD Stem Cell Mobilization and Apheresis Using Motixafortide |
| 2028-01 | US | CELC | Celcuity Inc. | Phase 1/Phase 2 | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer |
| 2028-01 | US | CHRS | Coherus Oncology, Inc. | Phase 1 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors |
| 2028-01 | US | CRMD | CorMedix Inc. | Phase 3 | Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) |
| 2028-01 | US | CYDY | CytoDyn Inc. | Phase 2 | The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER) |
| 2028-01 | US | ELVN | Enliven Therapeutics, Inc. | Phase 1 | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants |
| 2028-01 | US | FATE | Fate Therapeutics, Inc. | Phase 1 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors |
| 2028-01 | US | IMTX | Immatics N.V. | Phase 3 | SUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma |
| 2028-01 | US | KPTI | Karyopharm Therapeutics Inc. | Phase 2 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. |
| 2028-01 | US | LXRX | Lexicon Pharmaceuticals, Inc. | Phase 1/Phase 2 | Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes |
| 2028-01 | US | MBX | MBX Biosciences, Inc. | Phase 3 | A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism |
| 2028-01 | US | NRIX | Nurix Therapeutics, Inc. | Phase 2 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton’s Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) |
| 2028-01 | US | OPK | OPKO Health, Inc. | Phase 1/Phase 2 | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma |
| 2028-01 | US | OGN | Organon & Co. | Phase 3 | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis |
| 2028-01 | US | RXRX | Recursion Pharmaceuticals, Inc. | Phase 1/Phase 2 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors |
| 2028-01 | US | TYRA | Tyra Biosciences, Inc. | Phase 1 | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations |
| 2028-01-01 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Myopia Control: a Comparison Study Between Atropine and MiSight |
| 2028-01-01 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer |
| 2028-01-01 | US | STJO | St. Joseph, Inc. | Phase 2 | Fasudil Trial for Treatment of Early Alzheimer’s Disease (FEAD) |
| 2028-01-17 | US | AGIO | Agios Pharmaceuticals, Inc. | Phase 1 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria |
| 2028-01-25 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 1/Phase 2 | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors |
| 2028-01-27 | EU | VLA
XPAR | Valneva | Phase 3
partner: Pfizer | A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults |
| 2028-01-30 | EU | BSLN
XSWX | Basilea Pharmaceutica | Phase 3 | A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. |
| 2028-01-30 | US | MNKD | MannKind | Phase 2 | Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis |
| 2028-01-31 | Ex-US | SYMQY | SymBio Pharmaceuticals Limited | Phase 3 | A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT |
| 2028-01-31 | US | ANL | Adlai Nortye Ltd. | Phase 1 | Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations |
| 2028-01-31 | US | LEGN | Legend Biotech Corporation | Phase 1 | A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) |
| 2028-01-31 | US | CATX | Perspective Therapeutics, Inc. | Phase 1/Phase 2 | Lead-212 PSV359 Therapy for Patients With Solid Tumors |
| 2028-01-31 | US | STJO | St. Joseph, Inc. | Phase 3 | The Holistic Study |
| 2028-02 | EU | BSLN
XSWX | Basilea Pharmaceutica | Phase 3 | A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. |
| 2028-02 | EU | BAVA
XCSE | Bavarian Nordic | Phase 3 | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination |
| 2028-02 | Ex-US | BVNRY | Bavarian Nordic A/S | Phase 3 | Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination |
| 2028-02 | US | ACAD | ACADIA Pharmaceuticals Inc. | Phase 2 | Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis |
| 2028-02 | US | AGEN | Agenus Inc. | Phase 2 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma |
| 2028-02 | US | AKBA | Akebia Therapeutics, Inc. | Phase 2 | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G |
| 2028-02 | US | ALLO | Allogene Therapeutics, Inc. | Phase 1 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease |
| 2028-02 | US | BEAM | Beam Therapeutics Inc. | Phase 1/Phase 2 | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease |
| 2028-02 | US | BHVN | Biohaven Ltd. | Phase 1/Phase 2 | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors |
| 2028-02 | US | CLRB | Cellectar Biosciences, Inc. | Phase 1 | Phase 1 Study of CLR 125 in Triple Negative Breast Cancer |
| 2028-02 | US | LBRX | LB Pharmaceuticals Inc. | Phase 2 | Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. |
| 2028-02 | US | NXTC | NextCure, Inc. | Phase 1 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors |
| 2028-02 | US | TYRA | Tyra Biosciences, Inc. | Phase 2 | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer |
| 2028-02-01 | EU | ARGX
XBRU | argenx | Phase 1 | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy |
| 2028-02-03 | US | RAPP | Rapport Therapeutics, Inc. | Phase 2 | A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures |
| 2028-02-04 | US | MLTX | MoonLake Immunotherapeutics | Phase 3 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis |
| 2028-02-17 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 3 | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) |
| 2028-02-28 | Ex-US | JCRRF | JCR Pharmaceuticals Co., Ltd. | Phase 3 | An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects |
| 2028-02-28 | US | CTMX | CytomX Therapeutics, Inc. | Phase 1 | First In Human Study of CX-801 in Advanced Solid Tumors |
| 2028-02-28 | US | MRKR | Marker Therapeutics, Inc. | Phase 1 | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma |
| 2028-02-28 | US | MESO | Mesoblast Limited | Phase 3 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease |
| 2028-03 | EU | ABVX
XPAR | Abivax | Phase 2 | Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis |
| 2028-03 | EU | GMAB
XCSE | Genmab | Phase 3 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| 2028-03 | EU | HPHA
XFRA | Heidelberg Pharma | Phase 1/Phase 2 | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma |
| 2028-03 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors |
| 2028-03 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer |
| 2028-03 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC |
| 2028-03 | US | ARVN | Arvinas, Inc. | Phase 1 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. |
| 2028-03 | US | GNPX | Genprex, Inc. | Phase 1/Phase 2 | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib |
| 2028-03 | US | IMCR | Immunocore Holdings plc | Phase 3 | Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) |
| 2028-03 | US | NAMS | NewAmsterdam Pharma Company N.V. | Phase 3 | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome |
| 2028-03 | US | ORIC | ORIC Pharmaceuticals, Inc. | Phase 3 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) |
| 2028-03 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 3 | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder |
| 2028-03-01 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma |
| 2028-03-01 | US | IOVA | Iovance Biotherapeutics, Inc. | Phase 3 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. |
| 2028-03-01 | US | PSTV | Plus Therapeutics, Inc. | Phase 1 | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment |
| 2028-03-07 | EU | ARGX
XBRU | argenx | Phase 2 | ADAPT Forward 1 – ISA1 – a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod |
| 2028-03-08 | Ex-US | PYCXF | PYC THERAPEUTICS LTD. | Phase 1/Phase 2 | A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001 |
| 2028-03-15 | US | CGEM | Cullinan Therapeutics, Inc. | Phase 1 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren’s Disease |
| 2028-03-15 | US | HELP | Cybin Inc. | Phase 3 | Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) |
| 2028-03-21 | US | SLDB | Solid Biosciences Inc. | Phase 1 | A Study of SGT-212 Gene Therapy in Friedreich’s Ataxia |
| 2028-03-31 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study |
| 2028-03-31 | US | KYNB | Kyntra Bio, Inc. | Phase 2 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| 2028-03-31 | US | PBYI | Puma Biotechnology, Inc. | Phase 2 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) |
| 2028-04 | EU | ARGX
XBRU | argenx | Phase 2/Phase 3 | A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
| 2028-04 | EU | IPH
XPAR | Innate Pharma | Phase 1 | Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors |
| 2028-04 | US | RCUS | Arcus Biosciences, Inc. | Phase 3 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma |
| 2028-04 | US | ARQT | Arcutis Biotherapeutics, Inc. | Phase 1 | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 |
| 2028-04 | US | BCAX | Bicara Therapeutics Inc. | Phase 2/Phase 3 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
| 2028-04 | US | IPHA | Innate Pharma S.A. | Phase 1 | Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors |
| 2028-04 | US | TARA | Protara Therapeutics, Inc. | Phase 3 | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator’s Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer |
| 2028-04 | US | RCKT | Rocket Pharmaceuticals, Inc. | Phase 2 | A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease |
| 2028-04 | US | XNCR | Xencor, Inc. | Phase 1/Phase 2 | Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis |
| 2028-04-01 | US | CMPX | Compass Therapeutics, Inc. | Phase 1 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 |
| 2028-04-25 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer |
| 2028-04-30 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 3 | A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine |
| 2028-04-30 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 1 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors |
| 2028-04-30 | US | RGNX | REGENXBIO Inc. | Phase 3 | RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) |
| 2028-04-30 | US | RLAY | Relay Therapeutics, Inc. | Phase 3 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer |
| 2028-04-30 | US | VRCA | Verrica Pharmaceuticals Inc. | Phase 3 | Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) |
| 2028-05 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer |
| 2028-05 | US | ADPT | Adaptive Biotechnologies Corporation | Phase 2 | Department of Defense PTSD Adaptive Platform Trial – Intervention B – Vilazodone |
| 2028-05 | US | RNA | Avidity Biosciences, Inc. | Phase 3 | A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD |
| 2028-05 | US | BEAM | Beam Therapeutics Inc. | Phase 1/Phase 2 | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) |
| 2028-05 | US | IOVA | Iovance Biotherapeutics, Inc. | Phase 2 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. |
| 2028-05 | US | JANX | Janux Therapeutics, Inc. | Phase 1 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer |
| 2028-05 | US | MGNX | MacroGenics, Inc. | Phase 1 | A Study of MGC026 in Participants With Advanced Solid Tumors |
| 2028-05 | US | NKTR | Nektar Therapeutics | Phase 3 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis |
| 2028-05-10 | EU | ORNBV
XHEL | Orion Corporation | Phase 3
partner: MSD | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) |
| 2028-05-15 | Ex-US | GSGTF | GenSight Biologics S.A. | Phase 2 | Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients |
| 2028-05-25 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 3 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia |
| 2028-05-30 | US | CHRS | Coherus Oncology, Inc. | Phase 1 | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors |
| 2028-05-31 | EU | PHIL
XMIL | Philogen | Phase 1 | A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors |
| 2028-05-31 | Ex-US | ABSCF | AB Science S.A. | Phase 2 | Incretin Microdosing for Cardiometabolic Health in People With HIV |
| 2028-05-31 | US | CNTX | Context Therapeutics Inc. | Phase 1 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors |
| 2028-05-31 | US | PRAX | Praxis Precision Medicines, Inc. | Phase 3 | Clinical Trial of Vormatrigine in Adult Patients With Epilepsy |
| 2028-05-31 | US | ZNTL | Zentalis Pharmaceuticals, Inc. | Phase 3 | A Study of Azenosertib (ZN-c3) Versus Investigator’s Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression |
| 2028-06 | EU | ARGX
XBRU | argenx | Phase 3 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease |
| 2028-06 | EU | ARGX
XBRU | argenx | Phase 3 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease. |
| 2028-06 | EU | ARGX
XBRU | argenx | Phase 3 | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia |
| 2028-06 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 3 | Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension |
| 2028-06 | Ex-US | LYPHF | Luye Pharma Group Ltd. | Phase 3 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer |
| 2028-06 | US | ADPT | Adaptive Biotechnologies Corporation | Phase 2/Phase 3 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma |
| 2028-06 | US | CLDX | Celldex Therapeutics, Inc. | Phase 3 | A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ – ColdU and SD) |
| 2028-06 | US | CPHI | China Pharma Holdings, Inc. | Phase 3 | A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years |
| 2028-06 | US | IRON | Disc Medicine, Inc. | Phase 2/Phase 3 | HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP |
| 2028-06 | US | IMRX | Immuneering Corporation | Phase 3 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
| 2028-06 | US | NKTR | Nektar Therapeutics | Phase 3 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis |
| 2028-06 | US | RXRX | Recursion Pharmaceuticals, Inc. | Phase 1 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies |
| 2028-06 | US | REPL | Replimune, Inc. | Phase 2 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) |
| 2028-06 | US | SRRK | Scholar Rock Holding Corporation | Phase 2 | Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD |
| 2028-06 | US | STJO | St. Joseph, Inc. | Phase 2 | Testosterone Treatment in Men With Chronic Kidney Disease |
| 2028-06 | US | XNCR | Xencor, Inc. | Phase 1 | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis |
| 2028-06 | US | XENE | Xenon Pharmaceuticals Inc. | Phase 3 | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) |
| 2028-06-13 | US | MLTX | MoonLake Immunotherapeutics | Phase 3 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa |
| 2028-06-30 | EU | NANO
XPAR | Nanobiotix | Phase 3
partner: Johnson & Johnson | JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC |
| 2028-06-30 | Ex-US | JCRRF | JCR Pharmaceuticals Co., Ltd. | Phase 1/Phase 2 | A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB) |
| 2028-06-30 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | EMBRACE: Exercising Together |
| 2028-06-30 | US | GERN | Geron Corporation | Phase 3 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment |
| 2028-06-30 | US | TENX | Tenax Therapeutics, Inc. | Phase 3 | LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 |
| 2028-06-30 | US | ZLAB | Zai Lab Limited | Phase 3 | A Study of ZL-1310 Versus Investigator’s Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) |
| 2028-06-30 | US | ZNTL | Zentalis Pharmaceuticals, Inc. | Phase 1 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer |
| 2028-07 | EU | PHIL
XMIL | Philogen | Phase 2 | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients |
| 2028-07 | Ex-US | ASCLF | Ascletis Pharma Inc. | Phase 3 | A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes |
| 2028-07 | Ex-US | ASCLF | Ascletis Pharma Inc. | Phase 3 | A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
| 2028-07 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia |
| 2028-07 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 1/Phase 2 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma |
| 2028-07 | US | CPHI | China Pharma Holdings, Inc. | Phase 3 | A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes |
| 2028-07 | US | CPHI | China Pharma Holdings, Inc. | Phase 3 | A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
| 2028-07 | US | MJNA | Medical Marijuana, Inc. | Phase 1 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies |
| 2028-07-01 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC |
| 2028-07-01 | US | TGTX | TG Therapeutics, Inc. | Phase 2 | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) |
| 2028-07-08 | Ex-US | ABSCF | AB Science S.A. | Phase 2 | PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC |
| 2028-07-09 | EU | PHARM
XAMS | Pharming | Phase 3 | Pediatric Patients Aged 1 to 6 Years With APDS |
| 2028-07-09 | US | FTRE | Fortrea Holdings Inc. | Phase 3 | Pediatric Patients Aged 1 to 6 Years With APDS |
| 2028-07-09 | US | PHAR | Pharming Group N.V. | Phase 3 | Pediatric Patients Aged 1 to 6 Years With APDS |
| 2028-07-15 | US | MJNA | Medical Marijuana, Inc. | Phase 1/Phase 2 | CAR-T Immunotherapy Targeting CD19- ALL |
| 2028-07-16 | US | MRKR | Marker Therapeutics, Inc. | Phase 1 | MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer |
| 2028-08 | EU | ALM*
XMAD | Almirall | Phase 3 | A Study of Lebrikizumab in Adults With Nummular Eczema |
| 2028-08 | Ex-US | ALMRY | Almirall SA | Phase 3 | A Study of Lebrikizumab in Adults With Nummular Eczema |
| 2028-08 | Ex-US | LBTSF | Almirall, S.A. | Phase 3 | A Study of Lebrikizumab in Adults With Nummular Eczema |
| 2028-08 | US | DNLI | Denali Therapeutics Inc. | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease |
| 2028-08 | US | DNLI | Denali Therapeutics Inc. | Phase 1/Phase 2 | Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) |
| 2028-08 | US | KOD | Kodiak Sciences Inc. | Phase 3 | A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME – ALTO |
| 2028-08 | US | MDWD | MediWound Ltd. | Phase 2 | An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers |
| 2028-08 | US | OPK | OPKO Health, Inc. | Phase 1/Phase 2 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors |
| 2028-08 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 3 | Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis |
| 2028-08 | US | HOWL | Werewolf Therapeutics, Inc. | Phase 1/Phase 2 | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma |
| 2028-08 | US | ZLAB | Zai Lab Limited | Phase 1 | Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors |
| 2028-08-02 | EU | ORNBV
XHEL | Orion Corporation | Phase 3
partner: MSD | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) |
| 2028-08-23 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC |
| 2028-08-28 | US | SRPT | Sarepta Therapeutics, Inc. | Phase 1 | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) |
| 2028-08-31 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 3 | Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma |
| 2028-09 | EU | ARGX
XBRU | argenx | Phase 3 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy |
| 2028-09 | EU | GMAB
XCSE | Genmab | Phase 2 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers |
| 2028-09 | EU | MOLN
XSWX | Molecular Partners | Phase 1/Phase 2 | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors |
| 2028-09 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 1/Phase 2 | Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML |
| 2028-09 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 2/Phase 3 | Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria |
| 2028-09 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 3 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| 2028-09 | US | BHVN | Biohaven Ltd. | Phase 3 | A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy |
| 2028-09 | US | CLDX | Celldex Therapeutics, Inc. | Phase 3 | Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria |
| 2028-09 | US | CMPX | Compass Therapeutics, Inc. | Phase 2 | Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms |
| 2028-09 | US | RCKT | Rocket Pharmaceuticals, Inc. | Phase 1 | A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) |
| 2028-09 | US | GPCR | Structure Therapeutics Inc. | Phase 3 | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) |
| 2028-09 | US | GPCR | Structure Therapeutics Inc. | Phase 3 | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) |
| 2028-09 | US | XBIT | XBiotech Inc. | Phase 2 | Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy |
| 2028-09-15 | US | BCAB | BioAtla, Inc. | Phase 1 | Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. |
| 2028-09-18 | EU | PHARM
XAMS | Pharming | Phase 2 | Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation |
| 2028-09-18 | EU | ZEAL
XCSE | Zealand Pharma | Phase 3 | Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome |
| 2028-09-18 | Ex-US | ZLDPF | Zealand Pharma A/S | Phase 3 | Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome |
| 2028-09-18 | US | PHAR | Pharming Group N.V. | Phase 2 | Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation |
| 2028-09-30 | EU | PHIL
XMIL | Philogen | Phase 1 | A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis |
| 2028-10 | EU | ARGX
XBRU | argenx | Phase 2/Phase 3 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) |
| 2028-10 | EU | GMAB
XCSE | Genmab | Phase 3 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy |
| 2028-10 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer |
| 2028-10 | US | KYTX | Kyverna Therapeutics, Inc. | Phase 1/Phase 2 | KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
| 2028-10 | US | NKTX | Nkarta, Inc. | Phase 1/Phase 2 | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) |
| 2028-10 | US | NVCR | NovoCure Limited | Phase 3 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC |
| 2028-10 | US | XNCR | Xencor, Inc. | Phase 1 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases |
| 2028-10-15 | US | VSTM | Verastem, Inc. | Phase 3 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
| 2028-10-16 | US | KURA | Kura Oncology, Inc. | Phase 1/Phase 2 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia |
| 2028-10-23 | EU | ZEAL
XCSE | Zealand Pharma | Phase 3 | Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS |
| 2028-10-23 | Ex-US | ZLDPF | Zealand Pharma A/S | Phase 3 | Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS |
| 2028-10-29 | Ex-US | NURPF | Neuren Pharmaceuticals Limited | Phase 3 | An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome |
| 2028-10-30 | US | RXRX | Recursion Pharmaceuticals, Inc. | Phase 1/Phase 2 | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer |
| 2028-11 | EU | GMAB
XCSE | Genmab | Phase 1 | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab |
| 2028-11 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma |
| 2028-11 | Ex-US | PYCXF | PYC THERAPEUTICS LTD. | Phase 1 | Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 |
| 2028-11 | US | FDMT | 4D Molecular Therapeutics, Inc. | Phase 3 | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration |
| 2028-11 | US | ALMS | Alumis Inc. | Phase 3 | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis |
| 2028-11 | US | BBOT | BridgeBio Oncology Therapeutics, Inc. | Phase 1 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors |
| 2028-11 | US | LXEO | Lexeo Therapeutics, Inc. | Phase 1 | Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer’s Disease |
| 2028-11 | US | SRRK | Scholar Rock Holding Corporation | Phase 2 | A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy |
| 2028-11-02 | US | ZJYL | Jin Medical International Ltd. | Phase 2 | Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. |
| 2028-11-02 | US | TSHA | Taysha Gene Therapies, Inc. | Phase 1/Phase 2 | Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) |
| 2028-11-15 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) |
| 2028-11-30 | US | MJNA | Medical Marijuana, Inc. | Phase 1/Phase 2 | A Clinical Study of Arfolitixorin in Patients With mCRC |
| 2028-11-30 | US | RADX | Radiopharm Theranostics Limited | Phase 1/Phase 2 | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC |
| 2028-12 | EU | BAVA
XCSE | Bavarian Nordic | Phase 3 | A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. |
| 2028-12 | Ex-US | BVNRY | Bavarian Nordic A/S | Phase 3 | A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. |
| 2028-12 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1/Phase 2 | MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas |
| 2028-12 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 2 | A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren’s Syndrome |
| 2028-12 | US | APLS | Apellis Pharmaceuticals, Inc. | Phase 2 | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| 2028-12 | US | EIKN | Eikon Therapeutics, Inc. | Phase 1/Phase 2 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. |
| 2028-12 | US | IMTX | Immatics N.V. | Phase 1/Phase 2 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors |
| 2028-12 | US | INBX | Inhibrx Biosciences, Inc. | Phase 1 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
| 2028-12 | US | LBRX | LB Pharmaceuticals Inc. | Phase 3 | 52-week Open Label Safety-Tolerability Study |
| 2028-12 | US | MYGN | Myriad Genetics, Inc. | Phase 1 | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients’ Own Stem Cells |
| 2028-12 | US | OLMA | Olema Pharmaceuticals, Inc. | Phase 3 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer |
| 2028-12 | US | OTLC | Oncotelic Therapeutics, Inc. | Phase 2 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition |
| 2028-12 | US | PHVS | Pharvaris N.V. | Phase 3 | Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE |
| 2028-12 | US | TPST | Tempest Therapeutics, Inc. | Phase 3 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy |
| 2028-12 | US | RARE | Ultragenyx Pharmaceutical Inc. | Phase 1/Phase 2 | First-in-human Study of UX016 in GNEM |
| 2028-12 | US | VSTM | Verastem, Inc. | Phase 1/Phase 2 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors |
| 2028-12 | US | XNCR | Xencor, Inc. | Phase 1 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors |
| 2028-12-01 | US | NUVB | Nuvation Bio Inc. | Phase 3 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) |
| 2028-12-01 | US | TGTX | TG Therapeutics, Inc. | Phase 2 | Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia |
| 2028-12-12 | US | ZJYL | Jin Medical International Ltd. | Phase 2 | Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus |
| 2028-12-31 | Ex-US | ABSCF | AB Science S.A. | Phase 3 | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients |
| 2028-12-31 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome |
| 2028-12-31 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 3 | Statins In Intracerbral Hemorrhage |
| 2028-12-31 | Ex-US | LYPHF | Luye Pharma Group Ltd. | Phase 1/Phase 2 | LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation |
| 2028-12-31 | US | ANL | Adlai Nortye Ltd. | Phase 1 | A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression |
| 2028-12-31 | US | VCNX | Vaccinex, Inc. | Phase 1/Phase 2 | Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma |
| 2029-01 | EU | GMAB
XCSE | Genmab | Phase 1/Phase 2 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma |
| 2029-01 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer |
| 2029-01 | US | CGEM | Cullinan Therapeutics, Inc. | Phase 1/Phase 2 | A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA |
| 2029-01 | US | JBIO | Jade Biosciences, Inc. | Phase 2 | A Study of JADE101 in Participants With Immunoglobulin A Nephropathy |
| 2029-01 | US | MIST | Milestone Pharmaceuticals Inc. | Phase 3 | ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 |
| 2029-01 | US | NUVB | Nuvation Bio Inc. | Phase 3 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients |
| 2029-01 | US | PEPG | PepGen Inc. | Phase 2 | An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) |
| 2029-01 | US | SLDB | Solid Biosciences Inc. | Phase 3 | A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) |
| 2029-01-13 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC |
| 2029-01-15 | EU | ORNBV
XHEL | Orion Corporation | Phase 1/Phase 2
partner: MSD | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) |
| 2029-01-20 | EU | ARGX
XBRU | argenx | Phase 2 | A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults |
| 2029-01-30 | EU | PHIL
XMIL | Philogen | Phase 2 | A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma |
| 2029-01-31 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Feasibility of FMISO in Brain Tumors |
| 2029-02 | Ex-US | CASBF | CanSino Biologics Inc. | Phase 1 | Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine |
| 2029-02 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Defining the Ablative Dose for Y-90 TARE |
| 2029-02 | US | ACAD | ACADIA Pharmaceuticals Inc. | Phase 3 | Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis |
| 2029-02 | US | ALLO | Allogene Therapeutics, Inc. | Phase 1/Phase 2 | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) |
| 2029-02 | US | RARE | Ultragenyx Pharmaceutical Inc. | Phase 3 | Long-term Extension of GTX-102 in Angelman Syndrome |
| 2029-02-02 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT |
| 2029-02-28 | US | FDMT | 4D Molecular Therapeutics, Inc. | Phase 2 | 4D-150 in Patients With Diabetic Macular Edema |
| 2029-03 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas |
| 2029-03 | US | ABEO | Abeona Therapeutics Inc. | Phase 2/Phase 3 | Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH |
| 2029-03 | US | AGIO | Agios Pharmaceuticals, Inc. | Phase 3 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia |
| 2029-03 | US | RCUS | Arcus Biosciences, Inc. | Phase 1 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors |
| 2029-03 | US | BHVN | Biohaven Ltd. | Phase 1 | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors |
| 2029-03 | US | EIKN | Eikon Therapeutics, Inc. | Phase 1/Phase 2 | EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors |
| 2029-03 | US | MPLT | MapLight Therapeutics, Inc. | Phase 2 | An Open-Label Study of ML-007C-MA in Adults With Alzheimer’s Disease Psychosis |
| 2029-03 | US | RXRX | Recursion Pharmaceuticals, Inc. | Phase 1 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors |
| 2029-03 | US | TENX | Tenax Therapeutics, Inc. | Phase 3 | Long-Term Open-Label Extension Study of Oral Levosimendan |
| 2029-03 | US | RARE | Ultragenyx Pharmaceutical Inc. | Phase 1/Phase 2 | A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease |
| 2029-03 | US | RARE | Ultragenyx Pharmaceutical Inc. | Phase 2/Phase 3 | Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH |
| 2029-03 | US | QURE | uniQure N.V. | Phase 1/Phase 2 | Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington’s Disease |
| 2029-03 | US | WVE | Wave Life Sciences Ltd. | Phase 2 | Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy |
| 2029-03-02 | US | AUPH | Aurinia Pharmaceuticals Inc. | Phase 1/Phase 2 | Study of Aritinercept in Patients With Generalized Myasthenia Gravis |
| 2029-03-02 | US | SYRE | Spyre Therapeutics, Inc. | Phase 2 | Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD |
| 2029-03-31 | EU | PHARM
XAMS | Pharming | Phase 2 | Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease |
| 2029-03-31 | US | CELC | Celcuity Inc. | Phase 3 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) |
| 2029-03-31 | US | JSPR | Jasper Therapeutics, Inc. | Phase 3 | Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity. |
| 2029-03-31 | US | MJNA | Medical Marijuana, Inc. | Phase 1/Phase 2 | cfMSC Therapy for Diabetes |
| 2029-03-31 | US | PHAR | Pharming Group N.V. | Phase 2 | Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease |
| 2029-03-31 | US | STOK | Stoke Therapeutics, Inc. | Phase 2 | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome |
| 2029-04 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma |
| 2029-04 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 2/Phase 3 | ICP-332 in Subjects With Non-segmental Vitiligo |
| 2029-04 | US | ACIU | AC Immune SA | Phase 1/Phase 2 | A Study to Assess the Effects of ACI-24.060 in Alzheimer’s Disease and in Down Syndrome (ABATE Study) |
| 2029-04 | US | ACAD | ACADIA Pharmaceuticals Inc. | Phase 3 | ACP-204 in Adults With Alzheimer’s Disease Psychosis Open Label Extension Study |
| 2029-04 | US | NVCR | NovoCure Limited | Phase 3 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma |
| 2029-04 | US | VNDA | Vanda Pharmaceuticals Inc. | Phase 3 | Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis |
| 2029-04-02 | EU | PHM*
XMAD | PharmaMar | Phase 1/Phase 2 | Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies |
| 2029-04-05 | EU | GMAB
XCSE | Genmab | Phase 1 | A Study of GEN1106 in Participants With Solid Tumors |
| 2029-04-10 | Ex-US | ABSCF | AB Science S.A. | Phase 2 | Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance |
| 2029-05 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1/Phase 2 | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma |
| 2029-05 | US | ACAD | ACADIA Pharmaceuticals Inc. | Phase 3 | OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome |
| 2029-05 | US | RNA | Avidity Biosciences, Inc. | Phase 3 | A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping |
| 2029-05 | US | DCTH | Delcath Systems, Inc. | Phase 2 | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease |
| 2029-05 | US | INBX | Inhibrx Biosciences, Inc. | Phase 2/Phase 3 | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC |
| 2029-05 | US | MIRM | Mirum Pharmaceuticals, Inc. | Phase 2/Phase 3 | A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection |
| 2029-05 | US | NUVB | Nuvation Bio Inc. | Phase 3 | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma |
| 2029-05-01 | US | FATE | Fate Therapeutics, Inc. | Phase 1 | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors |
| 2029-05-28 | EU | ARGX
XBRU | argenx | Phase 2 | A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy |
| 2029-06 | EU | GMAB
XCSE | Genmab | Phase 1 | A Phase 1 Trial of GEN1119 in Participants With Solid Tumors |
| 2029-06 | EU | PRTC
XLON | PureTech | Phase 3 | Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) |
| 2029-06 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 3 | Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). |
| 2029-06 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 1 | Evaluation of ICP-B794 in Patients With Advanced Solid Tumors |
| 2029-06 | US | AGIO | Agios Pharmaceuticals, Inc. | Phase 3 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) |
| 2029-06 | US | RIGL | Rigel Pharmaceuticals, Inc. | Phase 2 | Study of Olutasidenib and Temozolomide in HGG |
| 2029-06 | US | RCKT | Rocket Pharmaceuticals, Inc. | Phase 1 | A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy |
| 2029-06 | US | SNDX | Syndax Pharmaceuticals, Inc. | Phase 3 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation |
| 2029-06 | US | TCRX | TScan Therapeutics, Inc. | Phase 3 | A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation |
| 2029-06 | US | QURE | uniQure N.V. | Phase 1/Phase 2 | Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington’s Disease |
| 2029-06 | US | XENE | Xenon Pharmaceuticals Inc. | Phase 3 | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) |
| 2029-06-01 | US | BYSI | BeyondSpring Inc. | Phase 3 | Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) |
| 2029-06-01 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia |
| 2029-06-24 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 2 | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia |
| 2029-06-30 | US | MJNA | Medical Marijuana, Inc. | Phase 1 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors |
| 2029-07 | EU | GMAB
XCSE | Genmab | Phase 3 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer |
| 2029-07 | Ex-US | INNMF | Amplia Therapeutics Limited | Phase 1/Phase 2 | A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer |
| 2029-07 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 1/Phase 2 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer |
| 2029-07 | US | RAPP | Rapport Therapeutics, Inc. | Phase 3 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 |
| 2029-07 | US | RAPP | Rapport Therapeutics, Inc. | Phase 3 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures |
| 2029-07 | US | REPL | Replimune, Inc. | Phase 1/Phase 2 | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies |
| 2029-07-01 | Ex-US | KHTRF | Knight Therapeutics Inc. | Phase 1/Phase 2 | A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors |
| 2029-07-01 | US | FATE | Fate Therapeutics, Inc. | Phase 2 | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis |
| 2029-07-29 | US | STJO | St. Joseph, Inc. | Phase 1 | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) |
| 2029-08 | EU | GMAB
XCSE | Genmab | Phase 3 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer |
| 2029-08 | EU | IDIA
XSWX | Idorsia | Phase 3 | A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease |
| 2029-08 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD |
| 2029-08 | Ex-US | IDRSF | Idorsia Ltd | Phase 3 | A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease |
| 2029-08 | US | AGIO | Agios Pharmaceuticals, Inc. | Phase 3 | A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) |
| 2029-08 | US | IMTX | Immatics N.V. | Phase 1 | ACTengine® IMA203 Combined With mRNA-4203 |
| 2029-08 | US | MBRX | Moleculin Biotech, Inc. | Phase 2/Phase 3 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML |
| 2029-08 | US | VIR | Vir Biotechnology, Inc. | Phase 1 | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors |
| 2029-08-01 | US | MJNA | Medical Marijuana, Inc. | Phase 2 | Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases |
| 2029-08-02 | US | URGN | UroGen Pharma Ltd. | Phase 1 | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC |
| 2029-08-30 | EU | PHM*
XMAD | PharmaMar | Phase 3 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) |
| 2029-09 | EU | ARGX
XBRU | argenx | Phase 2/Phase 3 | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis |
| 2029-09 | EU | ORNBV
XHEL | Orion Corporation | Phase 1/Phase 2 | A 2-part Phase 1/2 Open-label Trial on ODM-212 |
| 2029-09 | US | ANVS | Annovis Bio, Inc. | Phase 2/Phase 3 | A Study of Buntanetap in Participants With PD |
| 2029-09 | US | LXEO | Lexeo Therapeutics, Inc. | Phase 1/Phase 2 | Gene Therapy for Cardiomyopathy Associated With Friedreich’s Ataxia |
| 2029-09 | US | MRKR | Marker Therapeutics, Inc. | Phase 1 | Safety of MT-401-OTS in Patients With Relapsed AML or MDS |
| 2029-09 | US | RLMD | Relmada Therapeutics, Inc. | Phase 3 | A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer |
| 2029-09-30 | EU | ARGX
XBRU | argenx | Phase 2 | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| 2029-10 | Ex-US | PYCXF | PYC THERAPEUTICS LTD. | Phase 1/Phase 2 | Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle) |
| 2029-10 | US | MGTX | MeiraGTx Holdings plc | Phase 1/Phase 2 | Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson’s Disease |
| 2029-10 | US | NRIX | Nurix Therapeutics, Inc. | Phase 3 | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL |
| 2029-10-18 | EU | GMAB
XCSE | Genmab | Phase 1 | First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) |
| 2029-10-31 | Ex-US | JCRRF | JCR Pharmaceuticals Co., Ltd. | Phase 1/Phase 2 | Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA |
| 2029-11 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL |
| 2029-11-26 | US | CATX | Perspective Therapeutics, Inc. | Phase 1/Phase 2 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors |
| 2029-12 | EU | GMAB
XCSE | Genmab | Phase 3 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma |
| 2029-12 | EU | GMAB
XCSE | Genmab | Phase 3 | Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator’s Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer |
| 2029-12 | EU | OSE
XPAR | OSE Immunotherapeutics | Phase 1/Phase 2 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas |
| 2029-12 | EU | PHIL
XMIL | Philogen | Phase 1 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors |
| 2029-12 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 1 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers |
| 2029-12 | Ex-US | CSPHF | CStone Pharmaceuticals | Phase 3 | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma |
| 2029-12 | Ex-US | ORPOF | OSE IMMUNOTHERAPEUTICS | Phase 1/Phase 2 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas |
| 2029-12 | US | APGE | Apogee Therapeutics, Inc. | Phase 2 | A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis |
| 2029-12 | US | ELDN | Eledon Pharmaceuticals, Inc. | Phase 2 | Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients |
| 2029-12 | US | NUVL | Nuvalent, Inc. | Phase 3 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC |
| 2029-12 | US | PROK | ProKidney Corp. | Phase 3 | Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease |
| 2029-12 | US | STJO | St. Joseph, Inc. | Phase 1 | Gene Editing For Sickle Cell Disease |
| 2029-12-27 | Ex-US | ASPHF | Ascentage Pharma Group International | Phase 1 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL |
| 2029-12-31 | Ex-US | JBPHF | Jacobio Pharmaceuticals Group Co., Ltd. | Phase 1/Phase 2 | Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations |
| 2029-12-31 | US | ZJYL | Jin Medical International Ltd. | Phase 2 | A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma |
| 2029-12-31 | US | MJNA | Medical Marijuana, Inc. | Phase 1 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL |
| 2029-12-31 | US | MJNA | Medical Marijuana, Inc. | Phase 1/Phase 2 | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG |
| 2029-12-31 | US | STJO | St. Joseph, Inc. | Phase 3 | Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults |
| 2030-01 | US | ALLO | Allogene Therapeutics, Inc. | Phase 1 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma |
| 2030-01 | US | CNTX | Context Therapeutics Inc. | Phase 1 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers |
| 2030-01 | US | REPL | Replimune, Inc. | Phase 2/Phase 3 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma |
| 2030-01 | US | TYRA | Tyra Biosciences, Inc. | Phase 2 | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 |
| 2030-01 | US | RARE | Ultragenyx Pharmaceutical Inc. | Phase 2 | A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) |
| 2030-01-01 | US | MJNA | Medical Marijuana, Inc. | Phase 2/Phase 3 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features |
| 2030-01-01 | US | TGTX | TG Therapeutics, Inc. | Phase 2/Phase 3 | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis |
| 2030-02 | US | MPLT | MapLight Therapeutics, Inc. | Phase 2 | A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia |
| 2030-02 | US | VCEL | Vericel Corporation | Phase 3 | A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee |
| 2030-03 | US | STJO | St. Joseph, Inc. | Phase 2 | CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia |
| 2030-03-30 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 1 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors |
| 2030-03-31 | Ex-US | JCRRF | JCR Pharmaceuticals Co., Ltd. | Phase 2/Phase 3 | An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II |
| 2030-04 | US | RNA | Avidity Biosciences, Inc. | Phase 2 | Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) |
| 2030-04 | US | KURA | Kura Oncology, Inc. | Phase 1 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML |
| 2030-04-30 | EU | HNSA
XSTO | Hansa Biopharma | Phase 3 | A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group |
| 2030-04-30 | Ex-US | JCRRF | JCR Pharmaceuticals Co., Ltd. | Phase 1/Phase 2 | An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB |
| 2030-05 | EU | BAVA
XCSE | Bavarian Nordic | Phase 3 | An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults |
| 2030-05 | Ex-US | BVNRY | Bavarian Nordic A/S | Phase 3 | An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults |
| 2030-05 | US | CASI | CASI Pharmaceuticals, Inc. | Phase 1/Phase 2 | A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR). |
| 2030-05 | US | ORKA | Oruka Therapeutics, Inc. | Phase 2 | An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis |
| 2030-06-16 | US | CGON | CG Oncology, Inc. | Phase 3 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin |
| 2030-07 | US | VCEL | Vericel Corporation | Phase 3 | A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle |
| 2030-08 | US | RNA | Avidity Biosciences, Inc. | Phase 3 | Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 |
| 2030-08 | US | HRMY | Harmony Biosciences Holdings, Inc. | Phase 3 | A Study of Pitolisant in Participants With Prader-Willi Syndrome |
| 2030-08 | US | TVTX | Travere Therapeutics, Inc. | Phase 3 | A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) |
| 2030-08-01 | US | OCUL | Ocular Therapeutix, Inc. | Phase 3 | Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study |
| 2030-08-30 | US | NUVB | Nuvation Bio Inc. | Phase 3 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) |
| 2030-09 | Ex-US | KSPHF | Kissei Pharmaceutical Co., Ltd. | Phase 2 | A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia |
| 2030-09 | US | HUMA | Humacyte, Inc. | Phase 2 | Study to Evaluate the Safety and Efficacy of Humacyte’s Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG) |
| 2030-09 | US | KYNB | Kyntra Bio, Inc. | Phase 3 | A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) |
| 2030-09 | US | NUVB | Nuvation Bio Inc. | Phase 2 | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease |
| 2030-09-30 | US | REPL | Replimune, Inc. | Phase 3 | VO and Nivolumab vs Physician’s Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] |
| 2030-10 | EU | ARGX
XBRU | argenx | Phase 3 | A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS) |
| 2030-10 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 1 | Metastatic Ewing’s Trial Testing Schedule Enhancement to Improve Outcomes |
| 2030-10 | US | IDYA | IDEAYA Biosciences, Inc. | Phase 3 | Neoadjuvant Darovasertib in Primary Uveal Melanoma |
| 2030-10 | US | TYRA | Tyra Biosciences, Inc. | Phase 2 | Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma |
| 2030-10-31 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma |
| 2030-11 | US | IMCR | Immunocore Holdings plc | Phase 1 | Study of IMC-S118AI in Type 1 Diabetes |
| 2030-11-25 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 2/Phase 3 | ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) |
| 2030-11-30 | US | RCUS | Arcus Biosciences, Inc. | Phase 3 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma |
| 2030-12 | EU | GMAB
XCSE | Genmab | Phase 1/Phase 2
partner: BioNTech | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer |
| 2030-12 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma |
| 2030-12 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 1/Phase 2 | Evaluation of ICP-B208 in Patients With Advanced Solid Tumors |
| 2030-12 | US | IOVA | Iovance Biotherapeutics, Inc. | Phase 2 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer |
| 2030-12-30 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | A Study of VG712 in Patients With Mycosis Fungoides |
| 2031-01 | EU | GMAB
XCSE | Genmab | Phase 1 | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors |
| 2031-02 | EU | PHIL
XMIL | Philogen | Phase 2 | L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) |
| 2031-02 | EU | PHIL
XMIL | Philogen | Phase 2 | L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma |
| 2031-02 | EU | PHIL
XMIL | Philogen | Phase 2 | L19IL2/TNF in Patients With Basal Cell Carcinoma |
| 2031-02 | US | DNLI | Denali Therapeutics Inc. | Phase 1/Phase 2 | A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome |
| 2031-02 | US | EWTX | Edgewise Therapeutics, Inc. | Phase 2 | Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy |
| 2031-03 | US | ATXS | Astria Therapeutics, Inc. | Phase 2 | A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema |
| 2031-03-31 | US | ARVN | Arvinas, Inc. | Phase 1/Phase 2 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors |
| 2031-04 | US | BBOT | BridgeBio Oncology Therapeutics, Inc. | Phase 1 | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer |
| 2031-05-21 | US | VERA | Vera Therapeutics, Inc. | Phase 2 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept |
| 2031-06 | US | ATXS | Astria Therapeutics, Inc. | Phase 3 | A Long-Term Study of Navenibart in Participants With Hereditary Angioedema |
| 2031-06 | US | TSHA | Taysha Gene Therapies, Inc. | Phase 3 | A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) |
| 2031-06 | US | TSHA | Taysha Gene Therapies, Inc. | Phase 3 | Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome |
| 2031-06-02 | Ex-US | MRCHF | H.U. Group Holdings, Inc. | Phase 2 | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies |
| 2031-06-25 | Ex-US | INCPF | InnoCare Pharma Limited | Phase 3 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
| 2031-06-30 | US | OPK | OPKO Health, Inc. | Phase 1/Phase 2 | Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors |
| 2031-07 | US | ARDX | Ardelyx, Inc. | Phase 3 | Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C |
| 2031-07 | US | RLAY | Relay Therapeutics, Inc. | Phase 2 | A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) |
| 2031-07-07 | US | STJO | St. Joseph, Inc. | Phase 3 | PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years |
| 2031-08 | US | BCRX | BioCryst Pharmaceuticals, Inc. | Phase 3 | Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies |
| 2031-10 | US | TARA | Protara Therapeutics, Inc. | Phase 2 | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
| 2031-10-22 | US | CADL | Candel Therapeutics, Inc. | Phase 3 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) |
| 2031-11 | US | KURA | Kura Oncology, Inc. | Phase 3 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML |
| 2031-11 | US | VIR | Vir Biotechnology, Inc. | Phase 2 | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. |
| 2031-12 | US | GLSI | Greenwich LifeSciences, Inc. | Phase 3 | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects |
| 2031-12-15 | US | STJO | St. Joseph, Inc. | Phase 3 | Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma |
| 2031-12-31 | Ex-US | ABSCF | AB Science S.A. | Phase 3 | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma |
| 2032-02 | US | MGTX | MeiraGTx Holdings plc | Phase 2 | Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia |
| 2032-05-31 | US | TGTX | TG Therapeutics, Inc. | Phase 3 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis |
| 2032-06 | US | IOVA | Iovance Biotherapeutics, Inc. | Phase 1/Phase 2 | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel |
| 2032-06 | US | LXEO | Lexeo Therapeutics, Inc. | Phase 2 | Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy |
| 2032-10-31 | US | IMNN | Imunon, Inc. | Phase 3 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer |
| 2032-11 | EU | GMAB
XCSE | Genmab | Phase 2 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma |
| 2032-12 | US | IOVA | Iovance Biotherapeutics, Inc. | Phase 2 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma |
| 2033-04 | US | XENE | Xenon Pharmaceuticals Inc. | Phase 3 | An Open-label Study of XEN1101 in Epilepsy |
| 2033-05 | US | NRIX | Nurix Therapeutics, Inc. | Phase 1/Phase 2 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies |
| 2033-07 | US | INBX | Inhibrx Biosciences, Inc. | Phase 1/Phase 2 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) |
| 2033-09-01 | US | IOVA | Iovance Biotherapeutics, Inc. | Phase 2 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma |
| 2033-10-31 | US | SRPT | Sarepta Therapeutics, Inc. | Phase 3 | A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study |
| 2034-03 | US | IOVA | Iovance Biotherapeutics, Inc. | Phase 1/Phase 2 | A Study of IOV-5001 in Adults With Advanced Solid Tumors |
| 2034-12 | US | STJO | St. Joseph, Inc. | Phase 2 | Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma |
| 2034-12-31 | US | ZJYL | Jin Medical International Ltd. | Phase 2 | Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea |
| 2035-10-26 | US | STJO | St. Joseph, Inc. | Phase 2 | Quantitative Assessment of Radiation-induced Neuroinflammation – A Proof of Principle Study |
| 2035-12 | US | EIKN | Eikon Therapeutics, Inc. | Phase 2/Phase 3 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. |
| 2035-12-31 | US | EIKN | Eikon Therapeutics, Inc. | Phase 2/Phase 3 | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. |
| 2037-11 | EU | GMAB
XCSE | Genmab | Phase 3 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma |
